Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19180993,distribution,"The distribution and elimination half-life (t(1/2alpha) and t(1/2beta)) of 131I-rhFIX were 0.82 and 9.34 h, respectively.",Biodistribution and pharmacokinetics of transgenic pig-produced recombinant human factor IX (rhFIX) in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19180993/),h,0.82,251,DB00100,Coagulation Factor IX
,19180993,t(1/2beta)),"The distribution and elimination half-life (t(1/2alpha) and t(1/2beta)) of 131I-rhFIX were 0.82 and 9.34 h, respectively.",Biodistribution and pharmacokinetics of transgenic pig-produced recombinant human factor IX (rhFIX) in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19180993/),h,9.34,252,DB00100,Coagulation Factor IX
,19180993,maximum concentration in the plasma (Cmax),The maximum concentration in the plasma (Cmax) and the area under the concentration versus time curve (AUC(INF)) of 131I-rhFIX in rats were 3.09% injected dose (ID)/g and 15.3 h x % ID/g.,Biodistribution and pharmacokinetics of transgenic pig-produced recombinant human factor IX (rhFIX) in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19180993/),%,3.09,253,DB00100,Coagulation Factor IX
,19180993,area under the concentration versus time curve (AUC(INF)),The maximum concentration in the plasma (Cmax) and the area under the concentration versus time curve (AUC(INF)) of 131I-rhFIX in rats were 3.09% injected dose (ID)/g and 15.3 h x % ID/g.,Biodistribution and pharmacokinetics of transgenic pig-produced recombinant human factor IX (rhFIX) in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19180993/),%·h,15.3,254,DB00100,Coagulation Factor IX
≥,33086400,trough concentrations,Emicizumab trough concentrations ≥ 50 µg/mL were maintained throughout the study.,Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33086400/),[μg] / [ml],50,1988,DB00100,Coagulation Factor IX
at,28688133,trough level,Background Patients with severe hemophilia B regularly administer prophylactic intravenous doses of clotting factor IX concentrate to maintain a trough level of at least 0.01 IU mL-1 in order to prevent joint bleeds.,In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28688133/),[iu] / [ml],0.01,3658,DB00100,Coagulation Factor IX
,33540485,mean residence time,DalcA demonstrated a 24-fold greater potency over BeneFIX and longer mean residence time (33.8 h).,"Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33540485/),h,33.8,4681,DB00100,Coagulation Factor IX
,33540485,bioavailability,"SC bioavailability 8.2% to 20.3%, beta half-life 53.9 to 106.9 h and Tmax 24 to 48 h.","Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33540485/),%,8.2,4682,DB00100,Coagulation Factor IX
,33540485,beta half-life,"SC bioavailability 8.2% to 20.3%, beta half-life 53.9 to 106.9 h and Tmax 24 to 48 h.","Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33540485/),h,53.9 to 106.9,4683,DB00100,Coagulation Factor IX
,33540485,Tmax,"SC bioavailability 8.2% to 20.3%, beta half-life 53.9 to 106.9 h and Tmax 24 to 48 h.","Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33540485/),h,24 to 48,4684,DB00100,Coagulation Factor IX
<,15569163,trough level,Some patients did not bleed in spite of a trough level of <1% and others did in spite of trough levels >3%.,"A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15569163/),,1,10167,DB00100,Coagulation Factor IX
>,15569163,trough levels,Some patients did not bleed in spite of a trough level of <1% and others did in spite of trough levels >3%.,"A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15569163/),,3,10168,DB00100,Coagulation Factor IX
,9869161,recovery,The mean FIX:C and FIX:Ag recovery of FIX-SD-15 was 1.08 and 0.89 IU/dl/IU/kg respectively with a mean half-life of 33.3 h for FIX:C and 25.6 h for FIX:Ag.,A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869161/),[iu] / [dl·iu·kg],1.08,10265,DB00100,Coagulation Factor IX
,9869161,recovery,The mean FIX:C and FIX:Ag recovery of FIX-SD-15 was 1.08 and 0.89 IU/dl/IU/kg respectively with a mean half-life of 33.3 h for FIX:C and 25.6 h for FIX:Ag.,A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869161/),[iu] / [dl·iu·kg],0.89,10266,DB00100,Coagulation Factor IX
,9869161,half-life,The mean FIX:C and FIX:Ag recovery of FIX-SD-15 was 1.08 and 0.89 IU/dl/IU/kg respectively with a mean half-life of 33.3 h for FIX:C and 25.6 h for FIX:Ag.,A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869161/),h,33.3,10267,DB00100,Coagulation Factor IX
,9869161,half-life,The mean FIX:C and FIX:Ag recovery of FIX-SD-15 was 1.08 and 0.89 IU/dl/IU/kg respectively with a mean half-life of 33.3 h for FIX:C and 25.6 h for FIX:Ag.,A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869161/),h,25.6,10268,DB00100,Coagulation Factor IX
,11260271,trough,"Computer-predicted trough levels of exogenous FIX:C during repeated doses of rFIX (50 U kg(-1)) and, conversely, doses (in U kg(-1)) needed to maintain a 1-U dL(-1) trough level showed little or no dependence on age.",Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11260271/),[u] / [dl],1,11136,DB00100,Coagulation Factor IX
,11260271,trough level,"During prophylaxis a 1-U dL(-1) trough level can normally be maintained by dosing every 2-3 days, the former schedule resulting in, on average, a 45% lower consumption of rFIX.",Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11260271/),[u] / [dl],1,11137,DB00100,Coagulation Factor IX
,32712218,half-life,"As compared to the published data on PK of pdFIX, Kedrion FIX displayed a longer half-life (22.37-55.73 hrs), reduced clearance, and regular volume of distribution at PK I by both NCA and OCM.","Non-Compartment and compartmental pharmacokinetics, efficacy, and safety of Kedrion FIX concentrate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32712218/),h,22.37-55.73,15666,DB00100,Coagulation Factor IX
∼,22110246,half-life (t(1/2)),"Current factor IX (FIX) products display a half-life (t(1/2)) of ∼ 18 hours, requiring frequent intravenous infusions for prophylaxis and treatment in patients with hemophilia B.",Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22110246/),h,18,22738,DB00100,Coagulation Factor IX
,22110246,activity terminal t(1/2),"With baseline subtraction, mean activity terminal t(1/2) and mean residence time for rFIXFc were 56.7 and 71.8 hours, respectively.",Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22110246/),h,56.7,22739,DB00100,Coagulation Factor IX
,22110246,mean residence time,"With baseline subtraction, mean activity terminal t(1/2) and mean residence time for rFIXFc were 56.7 and 71.8 hours, respectively.",Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22110246/),h,71.8,22740,DB00100,Coagulation Factor IX
,25990590,AsBR,"The mean and median AsBR were 1.25, and 1.13 respectively in the weekly prophylaxis arm.","Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25990590/),,1.25,23465,DB00100,Coagulation Factor IX
,25990590,AsBR,"The mean and median AsBR were 1.25, and 1.13 respectively in the weekly prophylaxis arm.","Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25990590/),,1.13,23466,DB00100,Coagulation Factor IX
,24452809,clearance (CL),"For a typical 73 kg patient, the clearance (CL), volume of the central compartment (V 1) and volume of distribution at steady state (V ss) were 2.39 dL/h, 71.4 dL and 198 dL, respectively.",Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24452809/),[dl] / [h],2.39,24069,DB00100,Coagulation Factor IX
,24452809,volume of the central compartment (V 1),"For a typical 73 kg patient, the clearance (CL), volume of the central compartment (V 1) and volume of distribution at steady state (V ss) were 2.39 dL/h, 71.4 dL and 198 dL, respectively.",Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24452809/),dl,71.4,24070,DB00100,Coagulation Factor IX
,24452809,volume of distribution at steady state (V ss),"For a typical 73 kg patient, the clearance (CL), volume of the central compartment (V 1) and volume of distribution at steady state (V ss) were 2.39 dL/h, 71.4 dL and 198 dL, respectively.",Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24452809/),dl,198,24071,DB00100,Coagulation Factor IX
,7740479,plasma half-life,"Rats received rhFIX (50 IU/kg once daily) for 28 days, and the plasma half-life was 5 h.",Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740479/),h,5,25809,DB00100,Coagulation Factor IX
,7740479,Peak plasma concentrations,Peak plasma concentrations of rhFIX and Mononine were 4-5 micrograms/ml.,Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740479/),[μg] / [ml],4-5,25810,DB00100,Coagulation Factor IX
,7740479,plasma half-lives,The mean plasma half-lives were 13.2 +/- 1.6 h for rhFIX and 13.3 +/- 1.6 h for Mononine.,Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740479/),h,13.2,25811,DB00100,Coagulation Factor IX
,7740479,plasma half-lives,The mean plasma half-lives were 13.2 +/- 1.6 h for rhFIX and 13.3 +/- 1.6 h for Mononine.,Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740479/),h,13.3,25812,DB00100,Coagulation Factor IX
≤,27513989,FIX activity,Patients were aged 1-65 years with FIX activity ≤ 2 IU dL-1 .,Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27513989/),[iu] / [dl],2,27843,DB00100,Coagulation Factor IX
>,27513989,trough exogenous FIX activity levels,"Results Simulation of a single intravenous infusion of rIX-FP (25-75 IU kg-1 ) predicted that the median trough exogenous FIX activity levels would remain > 5 IU dL-1 for up to 16 days in adolescents/adults aged ≥ 12 years, up to 12 days in children aged 6 to < 12 years, and up to 9.5 days in children aged < 6 years.",Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27513989/),[iu] / [dl],5,27844,DB00100,Coagulation Factor IX
,27513989,trough exogenous FIX activity levels,"Results Simulation of a single intravenous infusion of rIX-FP (25-75 IU kg-1 ) predicted that the median trough exogenous FIX activity levels would remain > 5 IU dL-1 for up to 16 days in adolescents/adults aged ≥ 12 years, up to 12 days in children aged 6 to < 12 years, and up to 9.5 days in children aged < 6 years.",Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27513989/),,12,27845,DB00100,Coagulation Factor IX
>,27513989,trough exogenous FIX activity levels,"For steady-state dosing, the median trough exogenous FIX activity levels were maintained at > 5 IU dL-1 for the duration of the dosing interval for the 25, 35 and 40 IU kg-1 weekly regimens and for 75 IU kg-1 every 14 days in adolescents/adults, and for the 35 and 40 IU kg-1 weekly regimens in children.",Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27513989/),[iu] / [dl],5,27846,DB00100,Coagulation Factor IX
,7482403,recovery,"The average recovery after infusions for presurgical pharmacokinetic analysis (mean +/- standard deviation) was 1.28 +/- 0.56 U/dl rise per U/kg infused (range 0.41-2.80), and the average recovery after all infusions for treatment was 1.23 +/- 0.49 U/dl rise per U/kg infused (range - 0.35-2.92).",Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482403/),[u] / [dl·infused·kg·rise·u],1.28,32435,DB00100,Coagulation Factor IX
,7482403,recovery,"The average recovery after infusions for presurgical pharmacokinetic analysis (mean +/- standard deviation) was 1.28 +/- 0.56 U/dl rise per U/kg infused (range 0.41-2.80), and the average recovery after all infusions for treatment was 1.23 +/- 0.49 U/dl rise per U/kg infused (range - 0.35-2.92).",Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482403/),[u] / [dl·kg·rise·u],1.23,32436,DB00100,Coagulation Factor IX
,7482403,recovery,"Recovery values for multiple MAb Factor IX doses in a given patient were also variable; the average recovery was 1.22 +/- 0.53 U/dl rise per U/kg given, and standard deviations ranged from 0.03 to 1.26.",Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482403/),[u] / [dl·given·kg·rise·u],1.22,32437,DB00100,Coagulation Factor IX
,34013558,THL,THL of FVIII-EHL was longer than of FVIII standard half-life (SHL; median 15.1 vs. 11.1 h).,"Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34013558/),h,15.1,32474,DB00100,Coagulation Factor IX
,34013558,THL,THL of FVIII-EHL was longer than of FVIII standard half-life (SHL; median 15.1 vs. 11.1 h).,"Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34013558/),h,11.1,32475,DB00100,Coagulation Factor IX
,34013558,THL,THL of FIX-EHL was longer than of FIX-SHL (median 106.9 vs. 36.5 h).,"Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34013558/),h,106.9,32476,DB00100,Coagulation Factor IX
,34013558,THL,THL of FIX-EHL was longer than of FIX-SHL (median 106.9 vs. 36.5 h).,"Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34013558/),h,36.5,32477,DB00100,Coagulation Factor IX
,21812863,terminal elimination half-life,"Mean terminal elimination half-life was 27.6 h and 25.0 h, mean incremental recovery (IU dL(-1) /IU kg(-1)) was 1.55 and 1.60, at baseline and 3 months, respectively.","Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21812863/),h,27.6,33863,DB00100,Coagulation Factor IX
,21812863,terminal elimination half-life,"Mean terminal elimination half-life was 27.6 h and 25.0 h, mean incremental recovery (IU dL(-1) /IU kg(-1)) was 1.55 and 1.60, at baseline and 3 months, respectively.","Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21812863/),h,25.0,33864,DB00100,Coagulation Factor IX
,21812863,incremental recovery,"Mean terminal elimination half-life was 27.6 h and 25.0 h, mean incremental recovery (IU dL(-1) /IU kg(-1)) was 1.55 and 1.60, at baseline and 3 months, respectively.","Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21812863/),[iu·iu] / [dl·kg],1.55,33865,DB00100,Coagulation Factor IX
,21812863,incremental recovery,"Mean terminal elimination half-life was 27.6 h and 25.0 h, mean incremental recovery (IU dL(-1) /IU kg(-1)) was 1.55 and 1.60, at baseline and 3 months, respectively.","Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21812863/),[iu·iu] / [dl·kg],1.60,33866,DB00100,Coagulation Factor IX
≤,22764744,FIX activity,"A randomized, double-blind, non-inferiority, cross-over study conducted in participants aged ≥ 12 years weighing ≥ 40 kg, with severe or moderately severe haemophilia B (FIX activity ≤ 2 IU dL (-1) ).","Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22764744/),-1·dl·iu,2,34746,DB00100,Coagulation Factor IX
,22764744,Terminal phase half-lives,Terminal phase half-lives were similar (29.7 ± 18.2 h for IB1001 and 33.4 ± 21.2 h for nonacog alfa).,"Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22764744/),h,29.7,34747,DB00100,Coagulation Factor IX
,22764744,Terminal phase half-lives,Terminal phase half-lives were similar (29.7 ± 18.2 h for IB1001 and 33.4 ± 21.2 h for nonacog alfa).,"Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22764744/),h,33.4,34748,DB00100,Coagulation Factor IX
,10640322,plasma clearance,"In the monkey, FIX mAb had a plasma clearance of 0.6 ml/h/kg and a steady-state volume of distribution of approximately 70 ml/kg.",Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640322/),[ml] / [h·kg],0.6,42711,DB00100,Coagulation Factor IX
,10640322,steady-state volume of distribution,"In the monkey, FIX mAb had a plasma clearance of 0.6 ml/h/kg and a steady-state volume of distribution of approximately 70 ml/kg.",Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640322/),[ml] / [kg],70,42712,DB00100,Coagulation Factor IX
,10640322,elimination phase half-life,"The elimination phase half-life (3.8 days) was considerably less than other humanized IgG1 mAbs in the monkey, for which there is no binding to endogenous antigen.",Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640322/),d,3.8,42713,DB00100,Coagulation Factor IX
,10640322,time,The time for aPTT values to return to basal levels (25-170 h) increased with increasing dose.,Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640322/),h,25-170,42714,DB00100,Coagulation Factor IX
,10640322,half-life,The estimated Factor IX half-life was 11 h and the third-order association rate constant was 3.96 x 10(3) microM(-2) h(-1).,Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640322/),h,11,42715,DB00100,Coagulation Factor IX
,10640322,third-order association rate constant,The estimated Factor IX half-life was 11 h and the third-order association rate constant was 3.96 x 10(3) microM(-2) h(-1).,Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640322/),1/[(μM)^2·h],3.96 x 10(3),42716,DB00100,Coagulation Factor IX
,8004880,clearance,Median clearance was low--31.0 ml/hr.,Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),[ml] / [h],31.0,44008,DB00100,Coagulation Factor IX
,8004880,mean residence time,"In nonbleeding episodes, median mean residence time was 3.44 hours and median half-life was 2.89 hours.",Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),h,3.44,44009,DB00100,Coagulation Factor IX
,8004880,half-life,"In nonbleeding episodes, median mean residence time was 3.44 hours and median half-life was 2.89 hours.",Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),h,2.89,44010,DB00100,Coagulation Factor IX
,8004880,mean residence time,"In bleeding episodes, the elimination rate appears to be higher, with a median mean residence time of 2.97 hours and a median half-life of 2.30 hours.",Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),h,2.97,44011,DB00100,Coagulation Factor IX
,8004880,half-life,"In bleeding episodes, the elimination rate appears to be higher, with a median mean residence time of 2.97 hours and a median half-life of 2.30 hours.",Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),h,2.30,44012,DB00100,Coagulation Factor IX
,8004880,Recovery,Recovery was 45.6% during nonbleeding conditions and 43.5% during bleeding episodes (p = 0.0006); it was statistically lower with the highest dose level than with the 17.5 and 35 micrograms/kg doses (p = 0.007).,Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),%,45.6,44013,DB00100,Coagulation Factor IX
,8004880,Recovery,Recovery was 45.6% during nonbleeding conditions and 43.5% during bleeding episodes (p = 0.0006); it was statistically lower with the highest dose level than with the 17.5 and 35 micrograms/kg doses (p = 0.007).,Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),%,43.5,44014,DB00100,Coagulation Factor IX
,28159192,half-life,"Overall, rFIXFc exhibited a prolonged half-life of 68·6 h (95% CI 61·8-76·0), reduced clearance, and similar recovery compared with prestudy FIX.","Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159192/),h,68·6,51514,DB00100,Coagulation Factor IX
≤,28233381,FIX activity,"Data from 41 previously treated haemophilia B patients, enrolled globally (16 adolescents/adults and 25 children; FIX activity ≤0.02 IU mL-1 ) with no history of FIX inhibitors, were included.","Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28233381/),[iu] / [ml],0.02,53333,DB00100,Coagulation Factor IX
,28233381,Incremental recoveries,Incremental recoveries were 0.02 (IU mL-1 )/(IU kg-1 ) in both adolescents/adults and children.,"Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28233381/),1/[iu·iu·kg·ml],0.02,53334,DB00100,Coagulation Factor IX
,28233381,trough levels,The extended half-life resulted in mean trough levels of 0.27 IU mL-1 for adolescents/adults and 0.17 IU mL-1 for children at steady-state after weekly dosing at 40 IU kg-1 .,"Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28233381/),[iu] / [ml],0.27,53335,DB00100,Coagulation Factor IX
,28233381,trough levels,The extended half-life resulted in mean trough levels of 0.27 IU mL-1 for adolescents/adults and 0.17 IU mL-1 for children at steady-state after weekly dosing at 40 IU kg-1 .,"Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28233381/),[iu] / [ml],0.17,53336,DB00100,Coagulation Factor IX
,28233381,FIX,The population PK analysis confirmed a mono-exponential decay in FIX activity and allowed for predictions of FIX activity for adolescents/adults above 0.15 IU mL-1 at all times and 6.4 days week-1 in children.,"Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28233381/),[d] / [week],6.4,53337,DB00100,Coagulation Factor IX
,28233381,activity,The population PK analysis confirmed a mono-exponential decay in FIX activity and allowed for predictions of FIX activity for adolescents/adults above 0.15 IU mL-1 at all times and 6.4 days week-1 in children.,"Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28233381/),[d] / [week],6.4,53338,DB00100,Coagulation Factor IX
,21362109,half-life,"The mean half-life, in vivo response and recovery of Nonafact(®) were 18.7 (SD 2.0) h, 1.1 (SD 0.2) IU dL(-1) per IU kg(-1) b.w. of FIX infused and 49% (SD 10%), respectively.","An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362109/),h,18.7,54787,DB00100,Coagulation Factor IX
,21362109,in vivo response,"The mean half-life, in vivo response and recovery of Nonafact(®) were 18.7 (SD 2.0) h, 1.1 (SD 0.2) IU dL(-1) per IU kg(-1) b.w. of FIX infused and 49% (SD 10%), respectively.","An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362109/),[iu·iu] / [dl·kg],1.1,54788,DB00100,Coagulation Factor IX
,21362109,in vivo response,"The mean half-life, in vivo response and recovery of Nonafact(®) were 18.7 (SD 2.0) h, 1.1 (SD 0.2) IU dL(-1) per IU kg(-1) b.w. of FIX infused and 49% (SD 10%), respectively.","An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362109/),%,49,54789,DB00100,Coagulation Factor IX
,21362109,recovery,"The mean half-life, in vivo response and recovery of Nonafact(®) were 18.7 (SD 2.0) h, 1.1 (SD 0.2) IU dL(-1) per IU kg(-1) b.w. of FIX infused and 49% (SD 10%), respectively.","An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362109/),%,49,54790,DB00100,Coagulation Factor IX
,32314511,FIX,"FIX:C measurements were performed in rFIXFc-spiked plasma aliquots (targeted FIX levels of 1.5, 1, 0.5, 0.2, 0.05, 0.02 and 0.01 IU/mL) and plasma samples collected from two patients with HB at various time points after rFIXFc infusion, using three instruments (STA-R MAX, ACLTOP700 and CS2100i) and common clotting and chromogenic FIX:C assays.",Measurements of eftrenonacog alfa by 19 different combinations reagents/instrument: A single-centre study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32314511/),,1,54912,DB00100,Coagulation Factor IX
,12614367,FIX:C plasma levels,"Twenty-eight patients (25 surgery, two trauma, one severe spontaneous haemorrhage) were enrolled to receive a therapeutic bolus dose followed by CIV infusion of factor IX (FIX) to maintain FIX:C plasma levels of 0.4-1.0 IU mL(-1) (i.e. 40-100%).",Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614367/),[iu] / [ml],0.4-1.0,55087,DB00100,Coagulation Factor IX
,12614367,FIX:C,Median FIX:C was 72-86% for all patients receiving FIX by CIV on all days.,Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614367/),%,72-86,55088,DB00100,Coagulation Factor IX
,9465843,half-life,"Analysis of concentrations and clotting factor activities showed notably that (1) fluindione has a long half-life (median, 69 hours), and (2) concentration that inhibits the synthesis of the clotting factors by 50% varied for each factor, with a median ranging from 0.25 to 2.05 mg.L-1 for factors VII and II, respectively.",Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9465843/),h,69,57086,DB00100,Coagulation Factor IX
,26626991,half-life,ACE910 exhibited a linear PK profile and had a half-life of ∼4 to 5 weeks.,"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26626991/),weeks,∼4,57426,DB00100,Coagulation Factor IX
,26626991,half-life,ACE910 exhibited a linear PK profile and had a half-life of ∼4 to 5 weeks.,"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26626991/),weeks,5,57427,DB00100,Coagulation Factor IX
,18025536,apparent elimination half-life,"The mean apparent elimination half-life was approximately 2 hours, and mean residence time was approximately 3 hours.",First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18025536/),h,2,58046,DB00100,Coagulation Factor IX
,18025536,mean residence time,"The mean apparent elimination half-life was approximately 2 hours, and mean residence time was approximately 3 hours.",First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18025536/),h,3,58047,DB00100,Coagulation Factor IX
,18025536,EC(90),Inhibition of vWF A1 binding activity was achieved with an EC(90) value of 2.0 mug/mL (151 nmol/L) and of platelet function with an EC(90) value of 2.6 mug/mL (196 nmol/L).,First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18025536/),[μg] / [ml],2.0,58048,DB00100,Coagulation Factor IX
,18025536,EC(90),Inhibition of vWF A1 binding activity was achieved with an EC(90) value of 2.0 mug/mL (151 nmol/L) and of platelet function with an EC(90) value of 2.6 mug/mL (196 nmol/L).,First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18025536/),[μg] / [ml],2.6,58049,DB00100,Coagulation Factor IX
,33709296,steady-state concentration,"At the average steady-state concentration across all regimens (53.5 µg/mL), the predicted mean annualized bleeding rate is 1.28, corresponding to a 94.0% reduction from baseline.",Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33709296/),[μg] / [ml],53.5,59748,DB00100,Coagulation Factor IX
,25854709,CL,"However, previous reports have shown that the CL of rFIX concentrates varies widely (4.2-11.4 mL kg(-1) h(-1) ).",The features of clearance in recombinant factor IX (BeneFIX(®) ). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854709/),[ml] / [h·kg],4.2-11.4,63165,DB00100,Coagulation Factor IX
,25854709,CL,The mean CL calculated from AUC was 3.8 ± 0.4 mL kg(-1) h(-1) (range = 3.3-4.3 mL kg(-1) h(-1) ).,The features of clearance in recombinant factor IX (BeneFIX(®) ). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854709/),[ml] / [h·kg],3.8,63166,DB00100,Coagulation Factor IX
,25854709,AUC,The mean CL calculated from AUC was 3.8 ± 0.4 mL kg(-1) h(-1) (range = 3.3-4.3 mL kg(-1) h(-1) ).,The features of clearance in recombinant factor IX (BeneFIX(®) ). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854709/),[ml] / [h·kg],3.8,63167,DB00100,Coagulation Factor IX
,25854709,CL,The mean CL calculated from IVR and distribution half-life was 4.4 ± 0.4 mL kg(-1) h(-1) (range = 4.0-5.1 mL kg(-1) h(-1) ).,The features of clearance in recombinant factor IX (BeneFIX(®) ). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854709/),[ml] / [h·kg],4.4,63168,DB00100,Coagulation Factor IX
,25854709,CL,The mean CL calculated from IVR and terminal half-life was 2.1 ± 0.5 mL kg(-1) h(-1) (range = 1.7-2.8 mL kg(-1) h(-1) ).,The features of clearance in recombinant factor IX (BeneFIX(®) ). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854709/),[ml] / [h·kg],2.1,63169,DB00100,Coagulation Factor IX
,25854709,CL,The mean CL during CI was 4.9 ± 0.6 mL kg(-1) h(-1) (range = 4.2-5.6 mL kg(-1) h(-1) ).,The features of clearance in recombinant factor IX (BeneFIX(®) ). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854709/),[ml] / [h·kg],4.9,63170,DB00100,Coagulation Factor IX
,25854709,CL,"In addition, when we simulated the theoretical CL using a one-compartment model, the adjusted mean CL during CI was 4.8 ± 0.5 mL kg(-1) h(-1) (range = 4.0-5.4 mL kg(-1) h(-1) ).",The features of clearance in recombinant factor IX (BeneFIX(®) ). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854709/),[ml] / [h·kg],4.8,63171,DB00100,Coagulation Factor IX
,7957517,t1/2 beta,"The final mean values were t1/2 beta = 34 h, MRTMI = 37 h, CLMI = 4.0 ml.h-1.kg-1 and Vss = 0.15 l.kg-1.",Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957517/),h,34,66278,DB00100,Coagulation Factor IX
,7957517,MRTMI,"The final mean values were t1/2 beta = 34 h, MRTMI = 37 h, CLMI = 4.0 ml.h-1.kg-1 and Vss = 0.15 l.kg-1.",Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957517/),h,37,66279,DB00100,Coagulation Factor IX
,7957517,CLMI,"The final mean values were t1/2 beta = 34 h, MRTMI = 37 h, CLMI = 4.0 ml.h-1.kg-1 and Vss = 0.15 l.kg-1.",Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957517/),[ml] / [h·kg],4.0,66280,DB00100,Coagulation Factor IX
,7957517,Vss,"The final mean values were t1/2 beta = 34 h, MRTMI = 37 h, CLMI = 4.0 ml.h-1.kg-1 and Vss = 0.15 l.kg-1.",Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957517/),[l] / [kg],0.15,66281,DB00100,Coagulation Factor IX
,30394056,clearance,Population PK parameter values for clearance and V1 were 284 mL h-170 kg-1 and 5450 mL70 kg-1.,Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30394056/),[ml] / [70·h·kg],284,69238,DB00100,Coagulation Factor IX
,30394056,V1,Population PK parameter values for clearance and V1 were 284 mL h-170 kg-1 and 5450 mL70 kg-1.,Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30394056/),[ml] / [70·kg],5450,69239,DB00100,Coagulation Factor IX
,30394056,CL,"For a typical 34-year-old patient receiving rFIX, clearance (CL), intercompartmental clearance (Q2, Q3), distribution volume of the central compartment (V1) and peripheral compartments (V2, V3) plus interpatient variability (%CV) were: CL, 284 mL h-170 kg-1 (18%); V1, 5450 mL70 kg-1 (19%); Q2, 110 mL h-170 kg-1; V2, 4800 mL70 kg-1; Q3, 1610 mL h-170 kg-1; V3, 2040 mL70 kg-1.",Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30394056/),[ml] / [70·h·kg],284,69240,DB00100,Coagulation Factor IX
,30394056,V1,"For a typical 34-year-old patient receiving rFIX, clearance (CL), intercompartmental clearance (Q2, Q3), distribution volume of the central compartment (V1) and peripheral compartments (V2, V3) plus interpatient variability (%CV) were: CL, 284 mL h-170 kg-1 (18%); V1, 5450 mL70 kg-1 (19%); Q2, 110 mL h-170 kg-1; V2, 4800 mL70 kg-1; Q3, 1610 mL h-170 kg-1; V3, 2040 mL70 kg-1.",Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30394056/),[ml] / [70·kg],5450,69241,DB00100,Coagulation Factor IX
,30394056,Q2,"For a typical 34-year-old patient receiving rFIX, clearance (CL), intercompartmental clearance (Q2, Q3), distribution volume of the central compartment (V1) and peripheral compartments (V2, V3) plus interpatient variability (%CV) were: CL, 284 mL h-170 kg-1 (18%); V1, 5450 mL70 kg-1 (19%); Q2, 110 mL h-170 kg-1; V2, 4800 mL70 kg-1; Q3, 1610 mL h-170 kg-1; V3, 2040 mL70 kg-1.",Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30394056/),[ml] / [70·h·kg],110,69242,DB00100,Coagulation Factor IX
,30394056,V2,"For a typical 34-year-old patient receiving rFIX, clearance (CL), intercompartmental clearance (Q2, Q3), distribution volume of the central compartment (V1) and peripheral compartments (V2, V3) plus interpatient variability (%CV) were: CL, 284 mL h-170 kg-1 (18%); V1, 5450 mL70 kg-1 (19%); Q2, 110 mL h-170 kg-1; V2, 4800 mL70 kg-1; Q3, 1610 mL h-170 kg-1; V3, 2040 mL70 kg-1.",Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30394056/),[ml] / [70·kg],4800,69243,DB00100,Coagulation Factor IX
,30394056,Q3,"For a typical 34-year-old patient receiving rFIX, clearance (CL), intercompartmental clearance (Q2, Q3), distribution volume of the central compartment (V1) and peripheral compartments (V2, V3) plus interpatient variability (%CV) were: CL, 284 mL h-170 kg-1 (18%); V1, 5450 mL70 kg-1 (19%); Q2, 110 mL h-170 kg-1; V2, 4800 mL70 kg-1; Q3, 1610 mL h-170 kg-1; V3, 2040 mL70 kg-1.",Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30394056/),[ml] / [70·h·kg],1610,69244,DB00100,Coagulation Factor IX
,30394056,V3,"For a typical 34-year-old patient receiving rFIX, clearance (CL), intercompartmental clearance (Q2, Q3), distribution volume of the central compartment (V1) and peripheral compartments (V2, V3) plus interpatient variability (%CV) were: CL, 284 mL h-170 kg-1 (18%); V1, 5450 mL70 kg-1 (19%); Q2, 110 mL h-170 kg-1; V2, 4800 mL70 kg-1; Q3, 1610 mL h-170 kg-1; V3, 2040 mL70 kg-1.",Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30394056/),[ml] / [70·kg],2040,69245,DB00100,Coagulation Factor IX
,21555744,half-life,"The half-life was 93 hours, which was 5 times higher than the patient's previous product.",Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21555744/),h,93,69360,DB00100,Coagulation Factor IX
,17938803,infusion rate,"The mean infusion rate of PCC was 7.9 ml/min, equivalent to 196.4 IU/min.",Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17938803/),[ml] / [min],7.9,71807,DB00100,Coagulation Factor IX
,17938803,infusion rate,"The mean infusion rate of PCC was 7.9 ml/min, equivalent to 196.4 IU/min.",Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17938803/),[iu] / [min],196.4,71808,DB00100,Coagulation Factor IX
,17938803,terminal half-life,"The median terminal half-life of FIX was 16.7 h, FII 59.7 h, FVII 4.2 h and FX 30.7 h.",Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17938803/),h,16.7,71809,DB00100,Coagulation Factor IX
,17938803,terminal half-life,"The median terminal half-life of FIX was 16.7 h, FII 59.7 h, FVII 4.2 h and FX 30.7 h.",Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17938803/),h,59.7,71810,DB00100,Coagulation Factor IX
,17938803,terminal half-life,"The median terminal half-life of FIX was 16.7 h, FII 59.7 h, FVII 4.2 h and FX 30.7 h.",Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17938803/),h,4.2,71811,DB00100,Coagulation Factor IX
,17938803,terminal half-life,"The median terminal half-life of FIX was 16.7 h, FII 59.7 h, FVII 4.2 h and FX 30.7 h.",Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17938803/),h,30.7,71812,DB00100,Coagulation Factor IX
,17938803,in-vivo recovery,The median in-vivo recovery of FIX was 1.57 %/IU/kg and that of the other three coagulation factors > 2 %/IU/kg.,Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17938803/),[%] / [iu·kg],1.57,71813,DB00100,Coagulation Factor IX
>,17938803,in-vivo recovery,The median in-vivo recovery of FIX was 1.57 %/IU/kg and that of the other three coagulation factors > 2 %/IU/kg.,Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17938803/),[%] / [iu·kg],2,71814,DB00100,Coagulation Factor IX
,11739163,recovery,"Mean incremental rFIX recovery was 0.75 IU/dL per IU/kg, 30% lower than expected for pdFIX, although the mean half-life was similar.",Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11739163/),[iu] / [dl·iu·kg],0.75,72013,DB00100,Coagulation Factor IX
,3698349,plasma clearance,"Low serum albumin in NS patients induced a twofold increase of unbound warfarin vs controls (3.5% vs 1.8%, p less than 0.001) which led to a threefold increase in plasma clearance of warfarin (9.70 vs 3.26 ml X min-1, p less than 0.001); as warfarin distribution volume showed only a slight (non significant) increase in NS patients, the elimination half-life was thus markedly shortened in NS patients vs controls (18 vs 36 h, p less than 0.01).",Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698349/),[ml] / [min],9.70,75162,DB00100,Coagulation Factor IX
,3698349,plasma clearance,"Low serum albumin in NS patients induced a twofold increase of unbound warfarin vs controls (3.5% vs 1.8%, p less than 0.001) which led to a threefold increase in plasma clearance of warfarin (9.70 vs 3.26 ml X min-1, p less than 0.001); as warfarin distribution volume showed only a slight (non significant) increase in NS patients, the elimination half-life was thus markedly shortened in NS patients vs controls (18 vs 36 h, p less than 0.01).",Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698349/),[ml] / [min],3.26,75163,DB00100,Coagulation Factor IX
,3698349,elimination half-life,"Low serum albumin in NS patients induced a twofold increase of unbound warfarin vs controls (3.5% vs 1.8%, p less than 0.001) which led to a threefold increase in plasma clearance of warfarin (9.70 vs 3.26 ml X min-1, p less than 0.001); as warfarin distribution volume showed only a slight (non significant) increase in NS patients, the elimination half-life was thus markedly shortened in NS patients vs controls (18 vs 36 h, p less than 0.01).",Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698349/),h,18,75164,DB00100,Coagulation Factor IX
,3698349,elimination half-life,"Low serum albumin in NS patients induced a twofold increase of unbound warfarin vs controls (3.5% vs 1.8%, p less than 0.001) which led to a threefold increase in plasma clearance of warfarin (9.70 vs 3.26 ml X min-1, p less than 0.001); as warfarin distribution volume showed only a slight (non significant) increase in NS patients, the elimination half-life was thus markedly shortened in NS patients vs controls (18 vs 36 h, p less than 0.01).",Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698349/),h,36,75165,DB00100,Coagulation Factor IX
,27583313,terminal half-life,"The mean terminal half-life of rIX-FP was 91.4 hours (h), 4.3-fold longer than previous FIX treatment and clearance was 1.11 ml/h/kg, 6.4-fold slower than previous FIX treatment.",Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27583313/),(h)·h,91.4,76174,DB00100,Coagulation Factor IX
,27583313,clearance,"The mean terminal half-life of rIX-FP was 91.4 hours (h), 4.3-fold longer than previous FIX treatment and clearance was 1.11 ml/h/kg, 6.4-fold slower than previous FIX treatment.",Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27583313/),[ml] / [h·kg],1.11,76175,DB00100,Coagulation Factor IX
,27583313,annualised spontaneous bleeding rate,"The median (Q1, Q3) annualised spontaneous bleeding rate was 0.00 (0.00, 0.91) and was similar between the <6 years and ≥6 years age groups, with a weekly median prophylactic dose of 46 IU/kg.",Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27583313/),,0.00,76176,DB00100,Coagulation Factor IX
,27583313,trough level,"In addition, patients maintained a median trough level of 13.4 IU/dl FIX activity on weekly prophylaxis.",Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27583313/),[iu] / [dl],13.4,76177,DB00100,Coagulation Factor IX
,9873843,plasma trough level,Theoretical dosing regimens to maintain a plasma trough level of 1.0 U dL-1 of FIX:C were calculated.,Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873843/),[u] / [dl],1.0,76278,DB00100,Coagulation Factor IX
,23834666,annual,"Twice-weekly prophylaxis [mean duration 6.2 (±0.7) months; 1.8 (±0.1) infusions per week, 49.5 (±4.8) IU kg(-1) per infusion] was effective in preventing bleeding episodes, with a significantly lower (79%, P < 0.001) annualized bleed rate (4.2) compared to an on-demand treatment in a historical control group (20.0); 24 of 56 subjects on prophylaxis (43%) did not bleed throughout the study observation period.","Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23834666/),,4.,79583,DB00100,Coagulation Factor IX
,30453348,half-life,"The half-life of standard factor IX (FIX) concentrates is approximately 18 hours, which requires 2 or 3 intravenous infusions per week to achieve bleeding prevention in patients with severe haemophilia B.",Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30453348/),h,18,82449,DB00100,Coagulation Factor IX
,30453348,half-life,This sub-unit is responsible for the long half-life of the FXIII molecule (10-12 days).,Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30453348/),d,10-12,82450,DB00100,Coagulation Factor IX
,3082391,clearance rate,The mean factor IX clearance rate in eight factor IX-deficient patients was 233 mL/h (range 159 to 340 mL/h).,Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082391/),[ml] / [h],233,87395,DB00100,Coagulation Factor IX
,3082391,normalized clearance rate,The mean normalized clearance rate was 3.4 mL/h/kg.,Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082391/),[ml] / [h·kg],3.4,87396,DB00100,Coagulation Factor IX
,3082391,clearance rate,The mean factor VIII clearance rate in eight factor VIII-deficient patients was 294 mL/h (range 229 to 361 mL/h) and the mean normalized rate was 5.0 mL/h/kg.,Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082391/),[ml] / [h],294,87397,DB00100,Coagulation Factor IX
,3082391,normalized rate,The mean factor VIII clearance rate in eight factor VIII-deficient patients was 294 mL/h (range 229 to 361 mL/h) and the mean normalized rate was 5.0 mL/h/kg.,Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082391/),[ml] / [h·kg],5.0,87398,DB00100,Coagulation Factor IX
,11896334,in vivo recovery,The mean in vivo recovery in the pd-F IX group was 1.71 +/- 0.73 IU per dL per IU per kg compared with 0.86 +/- 0.31 IU per dL per IU per kg with r-F IX (p <or= 0.0001).,Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11896334/),[iu] / [dl·iu·kg],1.71,93849,DB00100,Coagulation Factor IX
,11896334,in vivo recovery,The mean in vivo recovery in the pd-F IX group was 1.71 +/- 0.73 IU per dL per IU per kg compared with 0.86 +/- 0.31 IU per dL per IU per kg with r-F IX (p <or= 0.0001).,Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11896334/),[iu] / [dl·iu·kg],0.86,93850,DB00100,Coagulation Factor IX
,33112889,Bioavailability,Bioavailability of subcutaneous dalcinonacog alfa was 10.3% in hemophilia B dogs.,"Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33112889/),%,10.3,102806,DB00100,Coagulation Factor IX
,17475604,FIX,"The infusion of 75 IU/kg of rFIX in our patients resulted in a mean FIX activity increase of 1.08 +/- 0.27 IU/dL per IU/kg with a range of 0.3-1.49 IU/dL per IU/kg, and a mean in vivo recovery of 44.0 +/- 9.5% with a range of 31.4-60.4%.",Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17475604/),[iu] / [dl·iu·kg],1.08,105141,DB00100,Coagulation Factor IX
,17475604,activity increase,"The infusion of 75 IU/kg of rFIX in our patients resulted in a mean FIX activity increase of 1.08 +/- 0.27 IU/dL per IU/kg with a range of 0.3-1.49 IU/dL per IU/kg, and a mean in vivo recovery of 44.0 +/- 9.5% with a range of 31.4-60.4%.",Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17475604/),[iu] / [dl·iu·kg],1.08,105142,DB00100,Coagulation Factor IX
,17475604,in vivo recovery,"The infusion of 75 IU/kg of rFIX in our patients resulted in a mean FIX activity increase of 1.08 +/- 0.27 IU/dL per IU/kg with a range of 0.3-1.49 IU/dL per IU/kg, and a mean in vivo recovery of 44.0 +/- 9.5% with a range of 31.4-60.4%.",Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17475604/),%,44.0,105143,DB00100,Coagulation Factor IX
,17475604,elimination half-life,The mean elimination half-life was 24.4 +/- 6.4 hours with a range of 14.1-35.3 hours.,Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17475604/),h,24.4,105144,DB00100,Coagulation Factor IX
,17475604,area under the curve,"The mean values of area under the curve, total body clearance, volume of distribution at steady state were 1363 +/- 166 IU x hour/dL, 4.84 +/- 1.03 mL/hour/kg, and 144.3 +/- 41.8 mL/kg, respectively.",Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17475604/),[h·iu] / [dl],1363,105145,DB00100,Coagulation Factor IX
,17475604,total body clearance,"The mean values of area under the curve, total body clearance, volume of distribution at steady state were 1363 +/- 166 IU x hour/dL, 4.84 +/- 1.03 mL/hour/kg, and 144.3 +/- 41.8 mL/kg, respectively.",Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17475604/),[ml] / [h·kg],4.84,105146,DB00100,Coagulation Factor IX
,17475604,volume of distribution at steady state,"The mean values of area under the curve, total body clearance, volume of distribution at steady state were 1363 +/- 166 IU x hour/dL, 4.84 +/- 1.03 mL/hour/kg, and 144.3 +/- 41.8 mL/kg, respectively.",Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17475604/),[ml] / [kg],144.3,105147,DB00100,Coagulation Factor IX
,34077951,apparent equilibrium dissociation constant (KD),"The resulting biAb (Mim8) assembled efficiently with FIXa and FX on membranes, and supported activation with an apparent equilibrium dissociation constant (KD) of 16 nM.",FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077951/),nM,16,107766,DB00100,Coagulation Factor IX
,34077951,KD,"Binding affinity with FIXa and FX in solution was much lower, with KD-values for FIXa and FX of 2.3 and 1.5 µM, respectively.",FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077951/),μM,2.3,107767,DB00100,Coagulation Factor IX
,34077951,KD,"Binding affinity with FIXa and FX in solution was much lower, with KD-values for FIXa and FX of 2.3 and 1.5 µM, respectively.",FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077951/),μM,1.5,107768,DB00100,Coagulation Factor IX
,34077951,half-life,"Furthermore, the pharmacokinetics of Mim8 were investigated and a half-life of 14 days demonstrated in cynomolgus monkey.",FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077951/),d,14,107769,DB00100,Coagulation Factor IX
,2128855,half-life,The mean half-life was 14.2 +/- 5.0 while recovery in predicted plasma volume was 72 +/- 12% corresponding to a response of 1.99 +/- 0.66 U/dL for every U/kg administered.,Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128855/),,14.2,117302,DB00100,Coagulation Factor IX
,2128855,recovery,The mean half-life was 14.2 +/- 5.0 while recovery in predicted plasma volume was 72 +/- 12% corresponding to a response of 1.99 +/- 0.66 U/dL for every U/kg administered.,Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128855/),%,72,117303,DB00100,Coagulation Factor IX
,31314609,half-life,"Changes of the FVIII molecule (single chain), pegylation of B-domain deleted FVIII, and fusion with Fc succeeded to improve the FVIII half-life, about 4 hours.",Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31314609/),h,4,119766,DB00100,Coagulation Factor IX
,33624121,Half-lives,"Half-lives were respectively 80, 104, and 82 h for N9-GP, rIX-FP, and rFIXFc versus 22 h for rFIX.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),h,80,120269,DB00100,Coagulation Factor IX
,33624121,Half-lives,"Half-lives were respectively 80, 104, and 82 h for N9-GP, rIX-FP, and rFIXFc versus 22 h for rFIX.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),h,104,120270,DB00100,Coagulation Factor IX
,33624121,Half-lives,"Half-lives were respectively 80, 104, and 82 h for N9-GP, rIX-FP, and rFIXFc versus 22 h for rFIX.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),h,82,120271,DB00100,Coagulation Factor IX
,33624121,Half-lives,"Half-lives were respectively 80, 104, and 82 h for N9-GP, rIX-FP, and rFIXFc versus 22 h for rFIX.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),h,22,120272,DB00100,Coagulation Factor IX
,33624121,area under the curve (AUC),"Between the EHL concentrates, exposure was different with area under the curve (AUC) values of 78.5, 49.6, and 12.1 IU/h/mL and time above FIX target values of 0.10 IU/mL of 168, 168, and 36 h for N9-GP, rIX-FP, and rFIXFc, respectively.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),[iu] / [h·ml],78.5,120273,DB00100,Coagulation Factor IX
,33624121,area under the curve (AUC),"Between the EHL concentrates, exposure was different with area under the curve (AUC) values of 78.5, 49.6, and 12.1 IU/h/mL and time above FIX target values of 0.10 IU/mL of 168, 168, and 36 h for N9-GP, rIX-FP, and rFIXFc, respectively.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),[iu] / [h·ml],49.6,120274,DB00100,Coagulation Factor IX
,33624121,area under the curve (AUC),"Between the EHL concentrates, exposure was different with area under the curve (AUC) values of 78.5, 49.6, and 12.1 IU/h/mL and time above FIX target values of 0.10 IU/mL of 168, 168, and 36 h for N9-GP, rIX-FP, and rFIXFc, respectively.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),[iu] / [h·ml],12.1,120275,DB00100,Coagulation Factor IX
,33624121,time above FIX,"Between the EHL concentrates, exposure was different with area under the curve (AUC) values of 78.5, 49.6, and 12.1 IU/h/mL and time above FIX target values of 0.10 IU/mL of 168, 168, and 36 h for N9-GP, rIX-FP, and rFIXFc, respectively.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),h,0.10,120276,DB00100,Coagulation Factor IX
,33624121,time above FIX,"Between the EHL concentrates, exposure was different with area under the curve (AUC) values of 78.5, 49.6, and 12.1 IU/h/mL and time above FIX target values of 0.10 IU/mL of 168, 168, and 36 h for N9-GP, rIX-FP, and rFIXFc, respectively.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),h,168,120277,DB00100,Coagulation Factor IX
,33624121,time above FIX,"Between the EHL concentrates, exposure was different with area under the curve (AUC) values of 78.5, 49.6, and 12.1 IU/h/mL and time above FIX target values of 0.10 IU/mL of 168, 168, and 36 h for N9-GP, rIX-FP, and rFIXFc, respectively.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),h,36,120278,DB00100,Coagulation Factor IX
,33624121,in vivo recovery,"N9-GP produced the highest median in vivo recovery value (1.70 IU/dL per IU/kg) compared with 1.18, 1.00, and 1.05 IU/dL per IU/kg for rIX-FP, rFIXFc, and rFIX, respectively.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),[iu] / [dl·iu·kg],1.70,120279,DB00100,Coagulation Factor IX
,33624121,in vivo recovery,"N9-GP produced the highest median in vivo recovery value (1.70 IU/dL per IU/kg) compared with 1.18, 1.00, and 1.05 IU/dL per IU/kg for rIX-FP, rFIXFc, and rFIX, respectively.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),[iu] / [dl·iu·kg],1.18,120280,DB00100,Coagulation Factor IX
,33624121,in vivo recovery,"N9-GP produced the highest median in vivo recovery value (1.70 IU/dL per IU/kg) compared with 1.18, 1.00, and 1.05 IU/dL per IU/kg for rIX-FP, rFIXFc, and rFIX, respectively.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),[iu] / [dl·iu·kg],1.00,120281,DB00100,Coagulation Factor IX
,33624121,in vivo recovery,"N9-GP produced the highest median in vivo recovery value (1.70 IU/dL per IU/kg) compared with 1.18, 1.00, and 1.05 IU/dL per IU/kg for rIX-FP, rFIXFc, and rFIX, respectively.",In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33624121/),[iu] / [dl·iu·kg],1.05,120282,DB00100,Coagulation Factor IX
,30248217,overall annualized bleeding rate (ABR),"In all patients receiving 40 IU/kg once-weekly, median overall annualized bleeding rate (ABR) was 1.03 (interquartile range 0.00; 2.89); median spontaneous ABR was 0.00 (0.00; 0.80).",Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30248217/),,1.03,125669,DB00100,Coagulation Factor IX
,30248217,spontaneous ABR,"In all patients receiving 40 IU/kg once-weekly, median overall annualized bleeding rate (ABR) was 1.03 (interquartile range 0.00; 2.89); median spontaneous ABR was 0.00 (0.00; 0.80).",Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30248217/),,0.00,125670,DB00100,Coagulation Factor IX
,12694518,recovery,The median recovery in the pd-FIX group was 1.67 IU dL(-1) per IU kg-1+/-1.07 vs.,Prophylaxis in factor IX deficiency product and patient variation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694518/),[iu] / [dl·iu·kg],1.67,128960,DB00100,Coagulation Factor IX
,12694518,half-life,The median half-life for pd-FIX was 12.9 +/-1.7 h compared with 13.7 +/- 2.9 h for r-FIX (P = 0.016).,Prophylaxis in factor IX deficiency product and patient variation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694518/),h,12.9,128961,DB00100,Coagulation Factor IX
,12694518,half-life,The median half-life for pd-FIX was 12.9 +/-1.7 h compared with 13.7 +/- 2.9 h for r-FIX (P = 0.016).,Prophylaxis in factor IX deficiency product and patient variation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694518/),h,13.7,128962,DB00100,Coagulation Factor IX
,3691761,clearance,The decay curves of Factor IX were evaluated by model-independent methods and the following pharmacokinetic parameters (mean +/- SD) were estimated: clearance (ml/h/kg) = 4.99 +/- 2.01; mean residence time (h) = 22.9 +/- 10.6; volume of distribution (ml/kg) = 99.9 +/- 35.5.,Single-dose pharmacokinetics of factor IX evaluated by model-independent methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691761/),[ml] / [h·kg],4.99,129984,DB00100,Coagulation Factor IX
,3691761,mean residence time,The decay curves of Factor IX were evaluated by model-independent methods and the following pharmacokinetic parameters (mean +/- SD) were estimated: clearance (ml/h/kg) = 4.99 +/- 2.01; mean residence time (h) = 22.9 +/- 10.6; volume of distribution (ml/kg) = 99.9 +/- 35.5.,Single-dose pharmacokinetics of factor IX evaluated by model-independent methods. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691761/),h,22.9,129985,DB00100,Coagulation Factor IX
,3691761,volume of distribution,The decay curves of Factor IX were evaluated by model-independent methods and the following pharmacokinetic parameters (mean +/- SD) were estimated: clearance (ml/h/kg) = 4.99 +/- 2.01; mean residence time (h) = 22.9 +/- 10.6; volume of distribution (ml/kg) = 99.9 +/- 35.5.,Single-dose pharmacokinetics of factor IX evaluated by model-independent methods. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691761/),[ml] / [kg],99.9,129986,DB00100,Coagulation Factor IX
,3691761,in vivo recovery,The in vivo recovery (59.8% +/- 16.9%) was found to be inversely correlated with the volume of distribution.,Single-dose pharmacokinetics of factor IX evaluated by model-independent methods. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691761/),%,59.8,129987,DB00100,Coagulation Factor IX
,14613933,t((1/2))alpha,"Disappearance of VWF from plasma was characterized by a rapid initial phase (t((1/2))alpha = 13 min) and a slow secondary phase (t((1/2))beta = 3 h), with a mean residence time (MRT) of 2.8 h.",An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613933/),min,13,134444,DB00100,Coagulation Factor IX
,14613933,t((1/2))beta,"Disappearance of VWF from plasma was characterized by a rapid initial phase (t((1/2))alpha = 13 min) and a slow secondary phase (t((1/2))beta = 3 h), with a mean residence time (MRT) of 2.8 h.",An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613933/),h,3,134445,DB00100,Coagulation Factor IX
,14613933,mean residence time (MRT),"Disappearance of VWF from plasma was characterized by a rapid initial phase (t((1/2))alpha = 13 min) and a slow secondary phase (t((1/2))beta = 3 h), with a mean residence time (MRT) of 2.8 h.",An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613933/),h,2.8,134446,DB00100,Coagulation Factor IX
,14613933,MRT,"Deletion of only the D'-D3 region was associated with an almost 2-fold lower recovery and increased clearance (MRT = 1.6 h), whereas deletion of only the D4-CK region resulted in a significantly reduced clearance (MRT = 4.5 h, p < 0.02).",An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613933/),h,1.6,134447,DB00100,Coagulation Factor IX
,14613933,clearance (MRT,"Furthermore, replacement of D3 domain residue Arg-1205 by His resulted in a markedly increased clearance (MRT = 0.3 h; p = 0.004).",An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613933/),h,0.3,134448,DB00100,Coagulation Factor IX
,28833808,annual bleed rate,"Prophylaxis (mean duration ± SD: 17.9 ± 9.6 months, mean dose: 55.5 ± 12.9 IU/kg, median 1.0 infusion per week) was effective in preventing bleeds (median annual bleed rate: 1.52, interquartile range: 0.0-3.46).","Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833808/),,1.52,134593,DB00100,Coagulation Factor IX
,7701550,recovery,"In the Immuninehep-plus crossover study (n = 27), Immuninehep-plus and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),[iu] / [dl·iu·kg],0.90,140250,DB00100,Coagulation Factor IX
,7701550,recovery,"In the Immuninehep-plus crossover study (n = 27), Immuninehep-plus and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),[iu] / [dl·iu·kg],0.84,140251,DB00100,Coagulation Factor IX
,7701550,compartmental half-life,"In the Immuninehep-plus crossover study (n = 27), Immuninehep-plus and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,17.11,140252,DB00100,Coagulation Factor IX
,7701550,compartmental half-life,"In the Immuninehep-plus crossover study (n = 27), Immuninehep-plus and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,15.94,140253,DB00100,Coagulation Factor IX
,7701550,effective half-life,"In the Immuninehep-plus crossover study (n = 27), Immuninehep-plus and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,16.51,140254,DB00100,Coagulation Factor IX
,7701550,effective half-life,"In the Immuninehep-plus crossover study (n = 27), Immuninehep-plus and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,16.48,140255,DB00100,Coagulation Factor IX
,7701550,recovery,"In the Immuninehep-minus crossover study (n = 26), Immuninehep-minus and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),[iu] / [dl·iu·kg],0.92,140256,DB00100,Coagulation Factor IX
,7701550,recovery,"In the Immuninehep-minus crossover study (n = 26), Immuninehep-minus and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),[iu] / [dl·iu·kg],1.02,140257,DB00100,Coagulation Factor IX
,7701550,compartmental half-life,"In the Immuninehep-minus crossover study (n = 26), Immuninehep-minus and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,17.42,140258,DB00100,Coagulation Factor IX
,7701550,compartmental half-life,"In the Immuninehep-minus crossover study (n = 26), Immuninehep-minus and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,18.77,140259,DB00100,Coagulation Factor IX
,7701550,effective half-life,"In the Immuninehep-minus crossover study (n = 26), Immuninehep-minus and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,16.39,140260,DB00100,Coagulation Factor IX
,7701550,effective half-life,"In the Immuninehep-minus crossover study (n = 26), Immuninehep-minus and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours.",Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701550/),h,16.48,140261,DB00100,Coagulation Factor IX
,22998153,peak,"A prophylactic regimen of 10 U kg(-1) N9-GP once weekly predicted mean peak and trough levels of 18 and 4.2 U dL(-1) , while 40 U kg(-1) once weekly predicted values of 72 and 17 U dL(-1) , respectively.","Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998153/),[u] / [dl],18,146397,DB00100,Coagulation Factor IX
,22998153,peak,"A prophylactic regimen of 10 U kg(-1) N9-GP once weekly predicted mean peak and trough levels of 18 and 4.2 U dL(-1) , while 40 U kg(-1) once weekly predicted values of 72 and 17 U dL(-1) , respectively.","Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998153/),[u] / [dl],72,146398,DB00100,Coagulation Factor IX
,22998153,trough levels,"A prophylactic regimen of 10 U kg(-1) N9-GP once weekly predicted mean peak and trough levels of 18 and 4.2 U dL(-1) , while 40 U kg(-1) once weekly predicted values of 72 and 17 U dL(-1) , respectively.","Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998153/),[u] / [dl],4.2,146399,DB00100,Coagulation Factor IX
,22998153,trough levels,"A prophylactic regimen of 10 U kg(-1) N9-GP once weekly predicted mean peak and trough levels of 18 and 4.2 U dL(-1) , while 40 U kg(-1) once weekly predicted values of 72 and 17 U dL(-1) , respectively.","Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998153/),[u] / [dl],72,146400,DB00100,Coagulation Factor IX
,22998153,trough levels,"A prophylactic regimen of 10 U kg(-1) N9-GP once weekly predicted mean peak and trough levels of 18 and 4.2 U dL(-1) , while 40 U kg(-1) once weekly predicted values of 72 and 17 U dL(-1) , respectively.","Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998153/),[u] / [dl],17,146401,DB00100,Coagulation Factor IX
,22998153,peak,"Standard prophylactic regimens with rFIX and pdFIX predicted mean peak and trough levels of 34 and 3.9 IU dL(-1) for rFIX, and mean values of 43 and 2.1 IU dL(-1) for pdFIX.","Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998153/),[iu] / [dl],34,146402,DB00100,Coagulation Factor IX
,22998153,peak,"Standard prophylactic regimens with rFIX and pdFIX predicted mean peak and trough levels of 34 and 3.9 IU dL(-1) for rFIX, and mean values of 43 and 2.1 IU dL(-1) for pdFIX.","Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998153/),[iu] / [dl],43,146403,DB00100,Coagulation Factor IX
,22998153,trough levels,"Standard prophylactic regimens with rFIX and pdFIX predicted mean peak and trough levels of 34 and 3.9 IU dL(-1) for rFIX, and mean values of 43 and 2.1 IU dL(-1) for pdFIX.","Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998153/),[iu] / [dl],3.9,146404,DB00100,Coagulation Factor IX
,22998153,trough levels,"Standard prophylactic regimens with rFIX and pdFIX predicted mean peak and trough levels of 34 and 3.9 IU dL(-1) for rFIX, and mean values of 43 and 2.1 IU dL(-1) for pdFIX.","Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22998153/),[iu] / [dl],2.1,146405,DB00100,Coagulation Factor IX
⁓,30151972,terminal half-life,"MarzAA showed linear dose-response PK across the 4.5-30 μg kg-1 dose range, with a terminal half-life of ⁓ 3.5 h.","Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30151972/),h,3.5,148692,DB00100,Coagulation Factor IX
,23537724,half-life,"Replacement therapy using recombinant or plasma-derived FIX is available, but the relatively short half-life of FIX (approximately 18 hours) necessitates administration every 2-3 days to prevent bleeding episodes.",PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23537724/),h,18,149842,DB00100,Coagulation Factor IX
,20056791,c,"Whole blood clotting time in FIX-deficient mice was corrected through 144 hours for rFIXFc, compared with 72 hours for rFIX; similar results were observed in FIX-deficient dogs.",Prolonged activity of factor IX as a monomeric Fc fusion protein. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20056791/),h,144,150157,DB00100,Coagulation Factor IX
,20056791,c,"Whole blood clotting time in FIX-deficient mice was corrected through 144 hours for rFIXFc, compared with 72 hours for rFIX; similar results were observed in FIX-deficient dogs.",Prolonged activity of factor IX as a monomeric Fc fusion protein. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20056791/),h,72,150158,DB00100,Coagulation Factor IX
,2094957,half-life,"When infused in patients with hemophilia B, monoclonal factor IX concentrate yielded a mean half-life of 34.6 +/- 13.1 (+/- SD) hours and in vivo recovery of 0.67 +/- 0.14 U/dL rise per each U/kg of factor IX infused.","Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2094957/),h,34.6,152606,DB00100,Coagulation Factor IX
,2094957,in vivo recovery,"When infused in patients with hemophilia B, monoclonal factor IX concentrate yielded a mean half-life of 34.6 +/- 13.1 (+/- SD) hours and in vivo recovery of 0.67 +/- 0.14 U/dL rise per each U/kg of factor IX infused.","Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2094957/),[u] / [dl·each·kg·rise·u],0.67,152607,DB00100,Coagulation Factor IX
,23647607,in vivo recovery (IVR),The outcomes of the comparison of the PK parameters were as follows: Mean (± SD) in vivo recovery (IVR) was 1.3 ± 0.4 IU dL(-1) per IU kg(-1) for AlphaNine(®) and 1.0 ± 0.3 IU dL(-1) per IU kg(-1) for BeneFIX(®) (P < 0.01).,Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23647607/),[iu·iu] / [dl·kg],1.3,157064,DB00100,Coagulation Factor IX
,23647607,in vivo recovery (IVR),The outcomes of the comparison of the PK parameters were as follows: Mean (± SD) in vivo recovery (IVR) was 1.3 ± 0.4 IU dL(-1) per IU kg(-1) for AlphaNine(®) and 1.0 ± 0.3 IU dL(-1) per IU kg(-1) for BeneFIX(®) (P < 0.01).,Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23647607/),[iu·iu] / [dl·kg],1.0,157065,DB00100,Coagulation Factor IX
,23647607,terminal half-life,"Mean terminal half-life, mean residence time, area under the curve, clearance and volume of distribution of BeneFIX(®) were 36.0 ± 12.8 h, 39.3 ± 13.9 h, 1631 ± 467 IU h dL(-1) , 0.046 ± 0.01 dL kg(-1) min(-1) and 1.75 ± 0.52 mL kg(-1) respectively.",Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23647607/),h,36.0,157066,DB00100,Coagulation Factor IX
,23647607,volume of distribution,"Mean terminal half-life, mean residence time, area under the curve, clearance and volume of distribution of BeneFIX(®) were 36.0 ± 12.8 h, 39.3 ± 13.9 h, 1631 ± 467 IU h dL(-1) , 0.046 ± 0.01 dL kg(-1) min(-1) and 1.75 ± 0.52 mL kg(-1) respectively.",Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23647607/),[ml] / [kg],1.75,157067,DB00100,Coagulation Factor IX
,17498071,overall spontaneous bleeding rate,"Favourable efficacy and safety profiles, consistent with those already well-established for original BeneFix, were observed: 81.1% of haemorrhages resolved with only a single infusion; 85.3% of initial treatment response ratings were Excellent or Good; more than half of the subjects using reformulated BeneFix for routine prophylaxis (11 of 17, 64.7%) had no spontaneous haemorrhages during their 6-12 month course of prophylactic treatment, with an overall spontaneous bleeding rate of 0.72 year(-1); and for the single surgical procedure (knee washing), treatment was rated Useful.",Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17498071/),1/[year],0.72,157074,DB00100,Coagulation Factor IX
,22281721,elimination half-life,"The median elimination half-life was 31 h, and the variation between individuals was modest both in PK and in dose requirement during twice-weekly prophylaxis.",Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281721/),h,31,157241,DB00100,Coagulation Factor IX
no more,27677190,half-life (HL),On-demand therapy and prophylaxis to treat or prevent bleedings is very demanding owing to the short half-life (HL) of factor concentrates (no more than 12-14 h for FVIII or 16-18 h for FIX).,Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27677190/),h,12-14,158140,DB00100,Coagulation Factor IX
,27677190,half-life (HL),On-demand therapy and prophylaxis to treat or prevent bleedings is very demanding owing to the short half-life (HL) of factor concentrates (no more than 12-14 h for FVIII or 16-18 h for FIX).,Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27677190/),h,16-18,158141,DB00100,Coagulation Factor IX
,27942241,half-life,The half-life of FIX seems to be longer than previously described and is expected to be 34 hours.,Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27942241/),h,34,163029,DB00100,Coagulation Factor IX
<,22726310,APTT,Prolonged PDs of rIX-FP were demonstrated with APTT<60 s sustained around four times longer with rIX-FP (5.9 days) than rFIX (1.5 days).,"Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22726310/),s,60,164198,DB00100,Coagulation Factor IX
,11307812,Bioavailability,"Bioavailability compared to IV administration was 11% for 200 IU/kg IT and 4.9% for 1,000 IU/kg.",Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307812/),%,11,167656,DB00100,Coagulation Factor IX
,11307812,Bioavailability,"Bioavailability compared to IV administration was 11% for 200 IU/kg IT and 4.9% for 1,000 IU/kg.",Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307812/),%,4.9,167657,DB00100,Coagulation Factor IX
,26755710,terminal half-life,"The mean terminal half-life of rIX-FP was 102 hours, 4.3-fold longer than previous FIX treatment.",Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26755710/),h,102,170406,DB00100,Coagulation Factor IX
,26755710,trough,"Patients maintained a mean trough of 20 and 12 IU/dL FIX activity on prophylaxis with rIX-FP 40 IU/kg weekly and 75 IU/kg every 2 weeks, respectively.",Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26755710/),[iu] / [dl],20,170407,DB00100,Coagulation Factor IX
,26755710,trough,"Patients maintained a mean trough of 20 and 12 IU/dL FIX activity on prophylaxis with rIX-FP 40 IU/kg weekly and 75 IU/kg every 2 weeks, respectively.",Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26755710/),[iu] / [dl],12,170408,DB00100,Coagulation Factor IX
,26755710,AsBR,The median AsBR was 0.00 for all prophylaxis regimens.,Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26755710/),,0.00,170409,DB00100,Coagulation Factor IX
,19659601,recovery,Mean recovery was 1.3 +/- 0.3 IU dL(-1) per IU kg(-1) for Factor IX Grifols and 1.0 +/- 0.3 IU dL(-1) per IU kg(-1) for control products (P < 0.001).,Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659601/),[iu·iu] / [dl·kg],1.3,170500,DB00100,Coagulation Factor IX
,19659601,recovery,Mean recovery was 1.3 +/- 0.3 IU dL(-1) per IU kg(-1) for Factor IX Grifols and 1.0 +/- 0.3 IU dL(-1) per IU kg(-1) for control products (P < 0.001).,Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659601/),[iu·iu] / [dl·kg],1.0,170501,DB00100,Coagulation Factor IX
,19659601,terminal half-life (t(1/2)),The mean terminal half-life (t(1/2)) for Factor IX Grifols was 26.7 h and 26.8 h for control product.,Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659601/),h,26.7,170502,DB00100,Coagulation Factor IX
,19659601,terminal half-life (t(1/2)),The mean terminal half-life (t(1/2)) for Factor IX Grifols was 26.7 h and 26.8 h for control product.,Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659601/),h,26.8,170503,DB00100,Coagulation Factor IX
>,26806557,trough FIX activity,The performance of individually calculated doses was compared with commonly prescribed FIX doses with respect to the number of patients with a trough FIX activity > 0.01 U mL(-1) .,Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26806557/),[u] / [ml],0.01,171918,DB00100,Coagulation Factor IX
,16236107,clearence (CL,PK values (PCC vs. HPFIX): clearence (CL; mL h(-1) kg(-1)) 5.2 +/- 1.4 vs.,"Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236107/),[ml] / [h·kg],5.2,178933,DB00100,Coagulation Factor IX
,16236107,volume of distribution at steady state,6.5 +/- 1.4; the volume of distribution at steady state (mL kg(-1)) 154.9 +/- 54.9 vs.,"Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236107/),[ml] / [kg],154.9,178934,DB00100,Coagulation Factor IX
,16236107,mean residence time,197.5 +/- 72.5; mean residence time (h) 29.7 +/- 8.1 vs.,"Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236107/),h,29.7,178935,DB00100,Coagulation Factor IX
,16236107,T(1/2),30.7 +/- 9.2; T(1/2) (h) 22.3 +/- 7 vs. 23.5 +/- 12.3; incremental recovery (IR; U dL(-1) U(-1) kg(-1)) 0.96 +/- 0.17 vs. 0.76 +/- 0.13.,"Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236107/),h,22.3,178936,DB00100,Coagulation Factor IX
,16236107,T(1/2),30.7 +/- 9.2; T(1/2) (h) 22.3 +/- 7 vs. 23.5 +/- 12.3; incremental recovery (IR; U dL(-1) U(-1) kg(-1)) 0.96 +/- 0.17 vs. 0.76 +/- 0.13.,"Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236107/),h,23.5,178937,DB00100,Coagulation Factor IX
,16236107,incremental recovery (IR,30.7 +/- 9.2; T(1/2) (h) 22.3 +/- 7 vs. 23.5 +/- 12.3; incremental recovery (IR; U dL(-1) U(-1) kg(-1)) 0.96 +/- 0.17 vs. 0.76 +/- 0.13.,"Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236107/),[u] / [dl·kg·u],0.96,178938,DB00100,Coagulation Factor IX
,16236107,incremental recovery (IR,30.7 +/- 9.2; T(1/2) (h) 22.3 +/- 7 vs. 23.5 +/- 12.3; incremental recovery (IR; U dL(-1) U(-1) kg(-1)) 0.96 +/- 0.17 vs. 0.76 +/- 0.13.,"Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236107/),[u] / [dl·kg·u],0.76,178939,DB00100,Coagulation Factor IX
,25721936,half-life in the circulation,"Recombinant Factor VIIa (rFVIIa) is utilized for on-demand treatment of bleeding episodes in hemophilia patients with neutralizing antibodies (inhibitors) against Factor VIII or Factor IX, but a short half-life in the circulation (~2.5hrs) limits its use in a prophylactic setting.",Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25721936/),h,2.5,179255,DB00100,Coagulation Factor IX
,3277474,half-life,"Heparin pharmacokinetics are poorly understood, but when the usual doses are given intravenously, heparin is rapidly removed from the blood and has a half-life of approximately 90 minutes.",Anticoagulation: a surgical perspective. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3277474/),min,90,181021,DB00100,Coagulation Factor IX
,27174727,steady-state FIX trough levels,Estimated mean steady-state FIX trough levels were 0.153 IU mL(-1) (0-6 years) and 0.190 IU mL(-1) (7-12 years).,Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174727/),[iu] / [ml],0.153,181808,DB00100,Coagulation Factor IX
,27174727,steady-state FIX trough levels,Estimated mean steady-state FIX trough levels were 0.153 IU mL(-1) (0-6 years) and 0.190 IU mL(-1) (7-12 years).,Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174727/),[iu] / [ml],0.190,181809,DB00100,Coagulation Factor IX
,12038784,bioavailability,Beagle dog SC bioavailability was 86.4% using a 2000 IU/mL formulation and 77.0% using a 4000 IU/mL formulation.,Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12038784/),%,86.4,189147,DB00100,Coagulation Factor IX
,12038784,bioavailability,Beagle dog SC bioavailability was 86.4% using a 2000 IU/mL formulation and 77.0% using a 4000 IU/mL formulation.,Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12038784/),%,77.0,189148,DB00100,Coagulation Factor IX
,12038784,bioavailability,Monkey bioavailability of a 4000 IU/mL formulation of rFIX was 34.8%.,Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12038784/),%,34.8,189149,DB00100,Coagulation Factor IX
,12038784,bioavailability,"A single SC administration of 200 IU/kg (4000 IU/mL) of rFIX to hemophilia B dogs, produced factor IX clotting activity above 5% for 5 days with a bioavailability of 48.6%.",Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12038784/),%,48.6,189150,DB00100,Coagulation Factor IX
,33051199,Ratio of half-life,Ratio of half-life between rFIX and rFIX-FP was 3.4-3.7.,"Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain. ",t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051199/),,3.4-3.7,190024,DB00100,Coagulation Factor IX
,23731351,clearance,The average FIX clearance was 8.4 mL h(-1) kg(-1) .,Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23731351/),[ml] / [h·kg],8.4,190740,DB00100,Coagulation Factor IX
,23731351,Elimination half-life,Elimination half-life ranged between 14 and 27 h.,Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23731351/),h,14 and 27,190741,DB00100,Coagulation Factor IX
,23731351,trough FIX level,"Doses to produce a target trough FIX level (set at 0.01 IU mL(-1) ) at 72 h predicted by the Bayesian analysis, with blood sampling at either 24, 48 and 72 h or at only 24 and 48 h, were within -40% to +67% of those predicted using the three-compartment model, and within -57% to +125% for targeting a level at 96 h.",Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23731351/),[iu] / [ml],0.01,190742,DB00100,Coagulation Factor IX
,24738137,half-life,The determined ACE910 pharmacokinetic parameters included a long half-life (3 weeks) and high subcutaneous bioavailability (nearly 100%).,Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738137/),weeks,3,191491,DB00100,Coagulation Factor IX
,24738137,subcutaneous bioavailability,The determined ACE910 pharmacokinetic parameters included a long half-life (3 weeks) and high subcutaneous bioavailability (nearly 100%).,Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738137/),%,100,191492,DB00100,Coagulation Factor IX
,11956506,volume of distribution,"Mean parameter estimates from individual fittings are 0.092 L/kg for volume of distribution, 0.15 L/kg for steady-state volume of distribution, and 0.0021 L/kg per hour for systemic clearance.",Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11956506/),[l] / [kg],0.092,201405,DB00100,Coagulation Factor IX
,11956506,steady-state volume of distribution,"Mean parameter estimates from individual fittings are 0.092 L/kg for volume of distribution, 0.15 L/kg for steady-state volume of distribution, and 0.0021 L/kg per hour for systemic clearance.",Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11956506/),[l] / [kg],0.15,201406,DB00100,Coagulation Factor IX
,11956506,systemic clearance,"Mean parameter estimates from individual fittings are 0.092 L/kg for volume of distribution, 0.15 L/kg for steady-state volume of distribution, and 0.0021 L/kg per hour for systemic clearance.",Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11956506/),[l] / [h·kg],0.0021,201407,DB00100,Coagulation Factor IX
,11956506,half-life,The estimated half-life of factor IX in blood was 21 hours.,Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11956506/),h,21,201408,DB00100,Coagulation Factor IX
,8839853,elimination half-life,"Based on activity data, the elimination half-life of rFIX was 18.9 +/- 2.3 hours and pdFIX was 17.9 +/- 2.1 hours.","Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839853/),h,18.9,201492,DB00100,Coagulation Factor IX
,8839853,elimination half-life,"Based on activity data, the elimination half-life of rFIX was 18.9 +/- 2.3 hours and pdFIX was 17.9 +/- 2.1 hours.","Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839853/),h,17.9,201493,DB00100,Coagulation Factor IX
,11735604,CL,"Typical average CL in patients with normal vWF levels is 3 ml/h/kg, with an apparent volume of distribution at steady state (Vss) that slightly exceeds the plasma volume of the patient, and the average elimination half-life (t1/2) is around 14 hours.",Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11735604/),[ml] / [h·kg],3,205345,DB00100,Coagulation Factor IX
,11735604,elimination half-life (t1/2),"Typical average CL in patients with normal vWF levels is 3 ml/h/kg, with an apparent volume of distribution at steady state (Vss) that slightly exceeds the plasma volume of the patient, and the average elimination half-life (t1/2) is around 14 hours.",Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11735604/),h,14,205346,DB00100,Coagulation Factor IX
,11735604,CL,"The average CL of plasma-derived FIX seems to be 4 ml/h/kg, the Vss is 3 to 4 times the plasma volume and the elimination t1/2 often exceeds 30 hours.",Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11735604/),[ml] / [h·kg],4,205347,DB00100,Coagulation Factor IX
exceeds,11735604,elimination t1/2,"The average CL of plasma-derived FIX seems to be 4 ml/h/kg, the Vss is 3 to 4 times the plasma volume and the elimination t1/2 often exceeds 30 hours.",Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11735604/),h,30,205348,DB00100,Coagulation Factor IX
,11735604,CL,"FVIIa has a much higher CL (average of 33 ml/h/kg), and a short terminal t1/2 (at 2 to 3 hours).",Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11735604/),[ml] / [h·kg],33,205349,DB00100,Coagulation Factor IX
,11735604,terminal t1/2,"FVIIa has a much higher CL (average of 33 ml/h/kg), and a short terminal t1/2 (at 2 to 3 hours).",Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11735604/),h,2 to 3,205350,DB00100,Coagulation Factor IX
,24304002,terminal half-life,"As compared with recombinant factor IX, rFIXFc exhibited a prolonged terminal half-life (82.1 hours) (P<0.001).",Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24304002/),h,82.1,206519,DB00100,Coagulation Factor IX
,24304002,annual,"The median annualized bleeding rates in groups 1, 2, and 3 were 3.0, 1.4, and 17.7, respectively.",Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24304002/),,3.0,206520,DB00100,Coagulation Factor IX
,24304002,annual,"The median annualized bleeding rates in groups 1, 2, and 3 were 3.0, 1.4, and 17.7, respectively.",Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24304002/),,1.4,206521,DB00100,Coagulation Factor IX
,24304002,annual,"The median annualized bleeding rates in groups 1, 2, and 3 were 3.0, 1.4, and 17.7, respectively.",Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24304002/),,17.7,206522,DB00100,Coagulation Factor IX
,21299747,recovery,Mean recovery was 1.01 ± 0.19 IU dL(-1) per IU kg(-1) at baseline and 1.23 ± 0.34 IU dL(-1) per IU kg(-1) 6 months later.,"A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21299747/),[iu·iu] / [dl·kg],1.01,207397,DB00100,Coagulation Factor IX
,21299747,recovery,Mean recovery was 1.01 ± 0.19 IU dL(-1) per IU kg(-1) at baseline and 1.23 ± 0.34 IU dL(-1) per IU kg(-1) 6 months later.,"A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21299747/),[iu·iu] / [dl·kg],1.23,207398,DB00100,Coagulation Factor IX
,21299747,Terminal half-life,"Terminal half-life was 34.5 ± 6.2 h and 33.7 ± 5.4 h, respectively.","A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21299747/),h,34.5,207399,DB00100,Coagulation Factor IX
,21299747,Terminal half-life,"Terminal half-life was 34.5 ± 6.2 h and 33.7 ± 5.4 h, respectively.","A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21299747/),h,33.7,207400,DB00100,Coagulation Factor IX
,9873772,half-life (T 1/2),We developed an aqueous-formulated human coagulation factor IX (hCFIX) with in vitro half-life (T 1/2) of 6 weeks at 37 degrees C and 18 months at 4 degrees C.,Novel delivery systems for coagulation proteins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873772/),weeks,6,207664,DB00100,Coagulation Factor IX
,9873772,half-life (T 1/2),We developed an aqueous-formulated human coagulation factor IX (hCFIX) with in vitro half-life (T 1/2) of 6 weeks at 37 degrees C and 18 months at 4 degrees C.,Novel delivery systems for coagulation proteins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873772/),month,18,207665,DB00100,Coagulation Factor IX
up to,9873772,bioavailability,"Upon bolus subcutaneous (s.c.) injection in animals, hCFIX had a bioavailability of up to 16% compared to intravenous (i.v.) dose.",Novel delivery systems for coagulation proteins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873772/),%,16,207666,DB00100,Coagulation Factor IX
up to,9873772,T 1/2,Freeze-dried human coagulation factor VIII (hCFVIII) formulated in non-aqueous solvents had in vitro T 1/2 up to 80 days at 37 degrees C.,Novel delivery systems for coagulation proteins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873772/),d,80,207667,DB00100,Coagulation Factor IX
,27333467,consumption,Median rIX-FP consumption for orthopaedic surgeries was 87 IU kg(-1) preoperatively and 375 IU kg(-1) overall.,Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27333467/),[iu] / [kg],87,208586,DB00100,Coagulation Factor IX
,27333467,consumption,Median rIX-FP consumption for orthopaedic surgeries was 87 IU kg(-1) preoperatively and 375 IU kg(-1) overall.,Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27333467/),[iu] / [kg],375,208587,DB00100,Coagulation Factor IX
,7259841,Ten-minute plasma recovery,Ten-minute plasma recovery average 35% (SD +/- 2) and the mean T 1/2 beta-phase elimination was 23 hr (+/- 5).,Labeled factor IX kinetics in patients with hemophilia-B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7259841/),%,35,211302,DB00100,Coagulation Factor IX
,7259841,T 1/2 beta-phase elimination,Ten-minute plasma recovery average 35% (SD +/- 2) and the mean T 1/2 beta-phase elimination was 23 hr (+/- 5).,Labeled factor IX kinetics in patients with hemophilia-B. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7259841/),h,23,211303,DB00100,Coagulation Factor IX
,22500821,maximum observed concentrations,"The mean maximum observed concentrations of pegnivacogin in cohorts 1, 1A, 2 and 3 at median time were 5.16 μg mL(-1) at 84 h, 5.19 μg mL(-1) at 72 h, 9.32 μg mL(-1) at 90 h, and 32.5 μg mL(-1) at 84 h, respectively.",A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500821/),[μg] / [ml],5.16,215932,DB00100,Coagulation Factor IX
,22500821,maximum observed concentrations,"The mean maximum observed concentrations of pegnivacogin in cohorts 1, 1A, 2 and 3 at median time were 5.16 μg mL(-1) at 84 h, 5.19 μg mL(-1) at 72 h, 9.32 μg mL(-1) at 90 h, and 32.5 μg mL(-1) at 84 h, respectively.",A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500821/),[μg] / [ml],5.19,215933,DB00100,Coagulation Factor IX
,22500821,maximum observed concentrations,"The mean maximum observed concentrations of pegnivacogin in cohorts 1, 1A, 2 and 3 at median time were 5.16 μg mL(-1) at 84 h, 5.19 μg mL(-1) at 72 h, 9.32 μg mL(-1) at 90 h, and 32.5 μg mL(-1) at 84 h, respectively.",A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500821/),[μg] / [ml],9.32,215934,DB00100,Coagulation Factor IX
,22500821,maximum observed concentrations,"The mean maximum observed concentrations of pegnivacogin in cohorts 1, 1A, 2 and 3 at median time were 5.16 μg mL(-1) at 84 h, 5.19 μg mL(-1) at 72 h, 9.32 μg mL(-1) at 90 h, and 32.5 μg mL(-1) at 84 h, respectively.",A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500821/),[μg] / [ml],32.5,215935,DB00100,Coagulation Factor IX
,22500821,maximum relative activated partial thromboplastin time,"The maximum relative activated partial thromboplastin time and time needed to achieve this were 1.18 at 2 days, 1.16 at 2 days, 1.27 at 3 days, and 1.85 at 2 days, respectively.",A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500821/),,1.18,215936,DB00100,Coagulation Factor IX
,22500821,maximum relative activated partial thromboplastin time,"The maximum relative activated partial thromboplastin time and time needed to achieve this were 1.18 at 2 days, 1.16 at 2 days, 1.27 at 3 days, and 1.85 at 2 days, respectively.",A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500821/),,1.16,215937,DB00100,Coagulation Factor IX
,22500821,maximum relative activated partial thromboplastin time,"The maximum relative activated partial thromboplastin time and time needed to achieve this were 1.18 at 2 days, 1.16 at 2 days, 1.27 at 3 days, and 1.85 at 2 days, respectively.",A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500821/),,1.27,215938,DB00100,Coagulation Factor IX
,22500821,time needed to achieve this,"The maximum relative activated partial thromboplastin time and time needed to achieve this were 1.18 at 2 days, 1.16 at 2 days, 1.27 at 3 days, and 1.85 at 2 days, respectively.",A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500821/),,1.27,215939,DB00100,Coagulation Factor IX
,22500821,time needed to achieve this,"The maximum relative activated partial thromboplastin time and time needed to achieve this were 1.18 at 2 days, 1.16 at 2 days, 1.27 at 3 days, and 1.85 at 2 days, respectively.",A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500821/),,1.85,215940,DB00100,Coagulation Factor IX
,22500821,half-life,"The calculated mean half-life and mean residence times of pegnivacogin were 6.12 days and 9.6 days, respectively.",A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500821/),d,6.12,215941,DB00100,Coagulation Factor IX
,22500821,mean residence times,"The calculated mean half-life and mean residence times of pegnivacogin were 6.12 days and 9.6 days, respectively.",A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500821/),d,9.6,215942,DB00100,Coagulation Factor IX
≥,32501555,trough concentrations,"The predicted trough concentrations were ≥1 IU/dL in 99% and 100% of subjects by the LLSM and Bayesian model, respectively.",Model-Based Evaluation of Linear Limited and Bayesian Sparse Sampling for Therapeutic Monitoring of Recombinant Coagulation Factor IX. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501555/),[iu] / [dl],1,217106,DB00100,Coagulation Factor IX
,32501555,trough concentrations,"The predicted trough concentrations were ≥1 IU/dL in 99% and 100% of subjects by the LLSM and Bayesian model, respectively.",Model-Based Evaluation of Linear Limited and Bayesian Sparse Sampling for Therapeutic Monitoring of Recombinant Coagulation Factor IX. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501555/),,99,217107,DB00100,Coagulation Factor IX
,32501555,trough concentrations,"The predicted trough concentrations were ≥1 IU/dL in 99% and 100% of subjects by the LLSM and Bayesian model, respectively.",Model-Based Evaluation of Linear Limited and Bayesian Sparse Sampling for Therapeutic Monitoring of Recombinant Coagulation Factor IX. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501555/),,100,217108,DB00100,Coagulation Factor IX
,32501555,AUC,"The average factor IX dose for a target AUC of 800 IU·h/dL was 61, 60, and 63 IU/kg using the extensive (reference), LLSM and Bayesian model, respectively.",Model-Based Evaluation of Linear Limited and Bayesian Sparse Sampling for Therapeutic Monitoring of Recombinant Coagulation Factor IX. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501555/),[iu] / [kg],800,217109,DB00100,Coagulation Factor IX
,32501555,AUC,"The average factor IX dose for a target AUC of 800 IU·h/dL was 61, 60, and 63 IU/kg using the extensive (reference), LLSM and Bayesian model, respectively.",Model-Based Evaluation of Linear Limited and Bayesian Sparse Sampling for Therapeutic Monitoring of Recombinant Coagulation Factor IX. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501555/),[iu] / [kg],61,217110,DB00100,Coagulation Factor IX
,32501555,AUC,"The average factor IX dose for a target AUC of 800 IU·h/dL was 61, 60, and 63 IU/kg using the extensive (reference), LLSM and Bayesian model, respectively.",Model-Based Evaluation of Linear Limited and Bayesian Sparse Sampling for Therapeutic Monitoring of Recombinant Coagulation Factor IX. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501555/),[iu] / [kg],60,217111,DB00100,Coagulation Factor IX
,32501555,AUC,"The average factor IX dose for a target AUC of 800 IU·h/dL was 61, 60, and 63 IU/kg using the extensive (reference), LLSM and Bayesian model, respectively.",Model-Based Evaluation of Linear Limited and Bayesian Sparse Sampling for Therapeutic Monitoring of Recombinant Coagulation Factor IX. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501555/),[iu] / [kg],63,217112,DB00100,Coagulation Factor IX
,28331929,terminal t½,"Prolonging the duration of the sample collection to 96 h resulted in a terminal t½ estimate of 39.6 ±7.4 h in the eight patients aged 18 years and older, which was longer than the estimates obtained using shorter periods of observation: 29.6 ± 5.5 h (truncated at 72 h) and 27.2 ± 7.0 h (truncated at 50 h).",Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28331929/),h,39.6,219427,DB00100,Coagulation Factor IX
,28331929,terminal t½,"Prolonging the duration of the sample collection to 96 h resulted in a terminal t½ estimate of 39.6 ±7.4 h in the eight patients aged 18 years and older, which was longer than the estimates obtained using shorter periods of observation: 29.6 ± 5.5 h (truncated at 72 h) and 27.2 ± 7.0 h (truncated at 50 h).",Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28331929/),h,29.6,219428,DB00100,Coagulation Factor IX
,28331929,terminal t½,"Prolonging the duration of the sample collection to 96 h resulted in a terminal t½ estimate of 39.6 ±7.4 h in the eight patients aged 18 years and older, which was longer than the estimates obtained using shorter periods of observation: 29.6 ± 5.5 h (truncated at 72 h) and 27.2 ± 7.0 h (truncated at 50 h).",Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28331929/),h,27.2,219429,DB00100,Coagulation Factor IX
,21299739,clearance (CL),"The average clearance (CL) of rFIX normally ranged between 7.5 and 9.1 mL h(-1) kg(-1), whereas that of pdFIX was 3.8-5.4 mL h(-1) kg(-1).",A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21299739/),[ml] / [h·kg],7.5 and 9.1,226110,DB00100,Coagulation Factor IX
,21299739,clearance (CL),"The average clearance (CL) of rFIX normally ranged between 7.5 and 9.1 mL h(-1) kg(-1), whereas that of pdFIX was 3.8-5.4 mL h(-1) kg(-1).",A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21299739/),[ml] / [h·kg],3.8-5.4,226111,DB00100,Coagulation Factor IX
,21299739,terminal half-life,"The average terminal half-life was 18-24 h among all 72-h studies on rFIX, in contrast to (normally) 29-43 h for pdFIX.",A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21299739/),h,18-24,226112,DB00100,Coagulation Factor IX
,21299739,terminal half-life,"The average terminal half-life was 18-24 h among all 72-h studies on rFIX, in contrast to (normally) 29-43 h for pdFIX.",A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21299739/),h,29-43,226113,DB00100,Coagulation Factor IX
,16850270,serum clearances,"For GPIbalpha-Ig/2V, the serum clearances were 2.62+/-0.27 ml/hr/kg in rats and 1.97+/-0.24 ml/hr/kg in dogs.",Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850270/),[ml] / [h·kg],2.62,229733,DB00100,Coagulation Factor IX
,16850270,serum clearances,"For GPIbalpha-Ig/2V, the serum clearances were 2.62+/-0.27 ml/hr/kg in rats and 1.97+/-0.24 ml/hr/kg in dogs.",Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850270/),[ml] / [h·kg],1.97,229734,DB00100,Coagulation Factor IX
,16850270,serum clearances,"The serum clearances of less potent GPIbalpha-Ig/1V were 1.08+/-0.08 and 0.97+/-0.19 ml/hr/kg in rats and dogs, respectively.",Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850270/),[ml] / [h·kg],1.08,229735,DB00100,Coagulation Factor IX
,16850270,serum clearances,"The serum clearances of less potent GPIbalpha-Ig/1V were 1.08+/-0.08 and 0.97+/-0.19 ml/hr/kg in rats and dogs, respectively.",Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850270/),[ml] / [h·kg],0.97,229736,DB00100,Coagulation Factor IX
,16850270,serum clearance,"In addition, the serum clearance of GPlbalpha-Ig/2V of 1.53 ml/hr/kg in vWF-deficient mice was lower than that in wild-type mice of 2.79 ml/hr/kg.",Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850270/),[ml] / [h·kg],1.53,229737,DB00100,Coagulation Factor IX
,16850270,serum clearance,"In addition, the serum clearance of GPlbalpha-Ig/2V of 1.53 ml/hr/kg in vWF-deficient mice was lower than that in wild-type mice of 2.79 ml/hr/kg.",Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850270/),[ml] / [h·kg],2.79,229738,DB00100,Coagulation Factor IX
≥,25209873,steady-state FIX trough levels,"Models predicted that rFIXFc administered 50 iu/kg weekly and 100 iu/kg every 10 d would maintain steady-state FIX trough levels ≥1 iu/dl in 95·4% and 89·2% of subjects, respectively.","Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25209873/),[iu] / [dl],1,234274,DB00100,Coagulation Factor IX
,22859609,half-life,"In the 50-IU/kg cohort (13 subjects), the mean half-life of rIX-FP was 92 hours, more than 5 times longer than the subjects' previous FIX product.",Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22859609/),h,92,239251,DB00100,Coagulation Factor IX
,22859609,FIX activity,"After 25 or 50 IU/kg rIX-FP administration, the baseline-corrected mean FIX activity remained elevated at day 7 (7.4 IU/dL and 13.4 IU/dL, respectively) and day 14 (2.5 IU/dL and 5.5 IU/dL, respectively).",Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22859609/),[iu] / [dl],7.4,239252,DB00100,Coagulation Factor IX
,22859609,FIX activity,"After 25 or 50 IU/kg rIX-FP administration, the baseline-corrected mean FIX activity remained elevated at day 7 (7.4 IU/dL and 13.4 IU/dL, respectively) and day 14 (2.5 IU/dL and 5.5 IU/dL, respectively).",Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22859609/),[iu] / [dl],13.4,239253,DB00100,Coagulation Factor IX
,22859609,FIX activity,"After 25 or 50 IU/kg rIX-FP administration, the baseline-corrected mean FIX activity remained elevated at day 7 (7.4 IU/dL and 13.4 IU/dL, respectively) and day 14 (2.5 IU/dL and 5.5 IU/dL, respectively).",Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22859609/),[iu] / [dl],2.5,239254,DB00100,Coagulation Factor IX
,22859609,FIX activity,"After 25 or 50 IU/kg rIX-FP administration, the baseline-corrected mean FIX activity remained elevated at day 7 (7.4 IU/dL and 13.4 IU/dL, respectively) and day 14 (2.5 IU/dL and 5.5 IU/dL, respectively).",Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22859609/),[iu] / [dl],5.5,239255,DB00100,Coagulation Factor IX
,22859609,incremental recovery,"The incremental recovery of rIX-FP was higher than both recombinant and plasma-derived FIX (1.4 vs 0.95 and 1.1 IU/dL per IU/kg, respectively).",Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22859609/),[iu] / [dl·iu·kg],1.4,239256,DB00100,Coagulation Factor IX
,22859609,incremental recovery,"The incremental recovery of rIX-FP was higher than both recombinant and plasma-derived FIX (1.4 vs 0.95 and 1.1 IU/dL per IU/kg, respectively).",Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22859609/),[iu] / [dl·iu·kg],0.95,239257,DB00100,Coagulation Factor IX
,22859609,incremental recovery,"The incremental recovery of rIX-FP was higher than both recombinant and plasma-derived FIX (1.4 vs 0.95 and 1.1 IU/dL per IU/kg, respectively).",Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22859609/),[iu] / [dl·iu·kg],1.1,239258,DB00100,Coagulation Factor IX
,25315324,peak recovery,Mean peak recovery at 10 min postinfusion was 62.14 IU dL(-1) with pdFIX and 52.7 IU dL(-1) with rFIX (P = 0.08).,Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25315324/),[iu] / [dl],62.14,242051,DB00100,Coagulation Factor IX
,25315324,peak recovery,Mean peak recovery at 10 min postinfusion was 62.14 IU dL(-1) with pdFIX and 52.7 IU dL(-1) with rFIX (P = 0.08).,Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25315324/),[iu] / [dl],52.7,242052,DB00100,Coagulation Factor IX
,25315324,half-life,Mean half-life was 16.6 h with pdFIX and 17.5 h with rFIX (P = 0.55).,Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25315324/),h,16.6,242053,DB00100,Coagulation Factor IX
,25315324,half-life,Mean half-life was 16.6 h with pdFIX and 17.5 h with rFIX (P = 0.55).,Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25315324/),h,17.5,242054,DB00100,Coagulation Factor IX
,25315324,Maximum peak thrombin generation (PTG),Maximum peak thrombin generation (PTG) was 35.9 nm with pdFIX and 28.9 nm with rFIX (P = 0.21).,Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25315324/),nm,35.9,242055,DB00100,Coagulation Factor IX
,25315324,Maximum peak thrombin generation (PTG),Maximum peak thrombin generation (PTG) was 35.9 nm with pdFIX and 28.9 nm with rFIX (P = 0.21).,Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25315324/),nm,28.9,242056,DB00100,Coagulation Factor IX
,33960073,alpha,"Pharmacokinetic findings (including mean alpha and beta half-life of 5.3 days and 3.9 days, respectively, and mean residence time of 6.2 days) supported prolonged effects.",Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33960073/),d,5.3,242831,DB00100,Coagulation Factor IX
,33960073,beta half-life,"Pharmacokinetic findings (including mean alpha and beta half-life of 5.3 days and 3.9 days, respectively, and mean residence time of 6.2 days) supported prolonged effects.",Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33960073/),d,3.9,242832,DB00100,Coagulation Factor IX
,33960073,mean residence time,"Pharmacokinetic findings (including mean alpha and beta half-life of 5.3 days and 3.9 days, respectively, and mean residence time of 6.2 days) supported prolonged effects.",Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33960073/),d,6.2,242833,DB00100,Coagulation Factor IX
,26969334,Cmax,"The FIX activity profiles showed multiphasic disposition characteristics, with initial mean (SD) PK profiles as follows: Cmax, 61.4 (12.5) IU/dL; AUC∞, 1055 (227) IU·h/dL; t½, 23.7 (5.6) hours; and recovery, 0.818 (0.167) IU/dL.","Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26969334/),[iu] / [dl],61.4,245461,DB00100,Coagulation Factor IX
,26969334,AUC∞,"The FIX activity profiles showed multiphasic disposition characteristics, with initial mean (SD) PK profiles as follows: Cmax, 61.4 (12.5) IU/dL; AUC∞, 1055 (227) IU·h/dL; t½, 23.7 (5.6) hours; and recovery, 0.818 (0.167) IU/dL.","Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26969334/),[h·iu] / [dl],1055,245462,DB00100,Coagulation Factor IX
,26969334,t½,"The FIX activity profiles showed multiphasic disposition characteristics, with initial mean (SD) PK profiles as follows: Cmax, 61.4 (12.5) IU/dL; AUC∞, 1055 (227) IU·h/dL; t½, 23.7 (5.6) hours; and recovery, 0.818 (0.167) IU/dL.","Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26969334/),h,23.7,245463,DB00100,Coagulation Factor IX
,26969334,recovery,"The FIX activity profiles showed multiphasic disposition characteristics, with initial mean (SD) PK profiles as follows: Cmax, 61.4 (12.5) IU/dL; AUC∞, 1055 (227) IU·h/dL; t½, 23.7 (5.6) hours; and recovery, 0.818 (0.167) IU/dL.","Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26969334/),[iu] / [dl],0.818,245464,DB00100,Coagulation Factor IX
,21545378,FIX:C,FIX:C was maintained at 100 IU dL(-1) in the immediate postoperative period.,"Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545378/),[iu] / [dl],100,253653,DB00100,Coagulation Factor IX
,21545378,hospital stay,Median hospital stay was 14 days (8-17).,"Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545378/),d,14,253654,DB00100,Coagulation Factor IX
,21545378,factor consumption,"During CI, factor consumption was 695 IU kg(-1), 691 IU kg(-1) and 495 IU kg(-1) for BeneFix®, Replenine® and Haemonine, respectively.","Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545378/),[iu] / [kg],695,253655,DB00100,Coagulation Factor IX
,21545378,factor consumption,"During CI, factor consumption was 695 IU kg(-1), 691 IU kg(-1) and 495 IU kg(-1) for BeneFix®, Replenine® and Haemonine, respectively.","Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545378/),[iu] / [kg],691,253656,DB00100,Coagulation Factor IX
,21545378,factor consumption,"During CI, factor consumption was 695 IU kg(-1), 691 IU kg(-1) and 495 IU kg(-1) for BeneFix®, Replenine® and Haemonine, respectively.","Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545378/),[iu] / [kg],495,253657,DB00100,Coagulation Factor IX
,1531035,biologic half-life (t1/2),"The in vivo recovery of factor IX with Mononine was a 0.67 +/- 0.14 U/dL (mean +/- SD) increase per 1U/kg of infused factor IX, and the biologic half-life (t1/2), determined using the terminal phase of elimination, was 22.6 +/- 8.1 hours.",Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531035/),h,22.6,256051,DB00100,Coagulation Factor IX
,1940573,III,The IXa-AT III titer was significantly reduced in three patients with severe factor VII deficiency (5.70 +/- 1.99 pmol/L) but was normal in three patients with severe factor XI deficiency (11.2 +/- 1.59 pmol/L).,Activated factor IX-antithrombin III complexes in human blood: quantification by an enzyme-linked differential antibody immunoassay and determination of the in vivo half-life. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940573/),[pM] / [l],5.70,268789,DB00100,Coagulation Factor IX
,1940573,titer,The IXa-AT III titer was significantly reduced in three patients with severe factor VII deficiency (5.70 +/- 1.99 pmol/L) but was normal in three patients with severe factor XI deficiency (11.2 +/- 1.59 pmol/L).,Activated factor IX-antithrombin III complexes in human blood: quantification by an enzyme-linked differential antibody immunoassay and determination of the in vivo half-life. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940573/),[pM] / [l],5.70,268790,DB00100,Coagulation Factor IX
,1940573,titer,The IXa-AT III titer was significantly reduced in three patients with severe factor VII deficiency (5.70 +/- 1.99 pmol/L) but was normal in three patients with severe factor XI deficiency (11.2 +/- 1.59 pmol/L).,Activated factor IX-antithrombin III complexes in human blood: quantification by an enzyme-linked differential antibody immunoassay and determination of the in vivo half-life. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940573/),[pM] / [l],11.2,268791,DB00100,Coagulation Factor IX
,1940573,half-life,Purified IXa-AT III was cleared in vivo in rabbits with a half-life value of 30 minutes.,Activated factor IX-antithrombin III complexes in human blood: quantification by an enzyme-linked differential antibody immunoassay and determination of the in vivo half-life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940573/),min,30,268792,DB00100,Coagulation Factor IX
